ALPHARMA INC
8-K, 1998-05-22
PHARMACEUTICAL PREPARATIONS
Previous: HUMMER WAYNE INVESTMENT TRUST, N-30D, 1998-05-22
Next: AMERITECH CORP /DE/, SC 13D/A, 1998-05-22







                          UNITED STATES
               SECURITIES AND EXCHANGE COMMISSION
                     WASHINGTON, DC  20549




                            FORM 8-K

                         CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934



Date of report (Date of earliest event reported):  May 7, 1998

                         Alpharma Inc.

       (Exact Name of Registrant as Specified in Charter)

                                            
      Delaware               1-8593              22-2095212
  (State or Other                                     
  Jurisdiction of       (Commission File      (I.R.S. Employer
   Incorporation)           Number)            Identification
                                                  Number)


One Executive Drive   Fort Lee, New Jersey                  07024

(Address of Principal Executive Offices)               (Zip code)


Registrant's telephone number, including area code: (201)947-7774


                         Not Applicable

 (Former Name or Former Address, if Changed Since Last Report)
Item  2.  Acquisition or Disposition of Assets

      On  May  7, 1998, Alpharma Inc. acquired all of the capital
stock  of Arthur H. Cox and Co. Ltd. and all of the capital stock
of certain related marketing subsidiaries ("Cox") from Hoechst AG
for  approximately $192 million in cash, the assumption  of  bank
debt  which was repaid subsequent to the closing, and  a  further
purchase price adjustment equal to any increase (or decrease)  in
the  net  assets  of  Cox from January 1, 1998  to  the  date  of
acquisition. Cox's main operations (which primarily consists of a
manufacturing   plant,  warehousing  facilities   and   a   sales
organization) are located in the United Kingdom with distribution
and  sales operations located in Scandinavia, the Netherlands and
Belgium.  Cox  is  a  generic  pharmaceutical  manufacturer   and
marketer  of tablets, capsules, suppositories, liquids, ointments
and  creams.  Cox distributes its products to pharmacy  retailers
and  pharmaceutical wholesalers primarily in the United  Kingdom.
The  Company  intends to continue the operation of  the  core  UK
business of Cox and to achieve benefits from leveraging  the  Cox
business  with the existing European pharmaceutical  business  of
Alpharma. The Company also intends to expand the scope  of  Cox's
operations  geographically and to add to Cox's  UK  product  base
certain other pharmaceutical products of the Company.

      The  Company  financed the $192 million  cash  payment  and
related debt repayments from borrowings under its existing  long-
term  Revolving Credit Facility and short-term lines  of  credit.
The $180 million Revolving Credit Facility ("RCF")(which includes
the  names of the banks participating therein) was used  to  fund
the  principal portion of the purchase price. At the end of March
1998,  the  Company repaid approximately $162 million  borrowings
under  the RCF with the proceeds from the issuance of convertible
subordinated notes as reported in the Company's current report on
Form  8-K  dated  March  30,  1998. Such  repayment  created  the
capacity  under the RCF to incur the borrowings used  to  finance
the  acquisition  of  Cox.  The  RCF  has  been  filed  with  the
Securities and Exchange Commission and is incorporated herein  by
reference.

Item  7.    Financial Statements, Pro Forma Financial Information
and Exhibits

     (a)  Financial Statements.

     As of the date of filing of this Current Report on Form 8-K,
it  is  impracticable for the Registrant to provide the financial
statements required by this Item 7(a). In accordance with Item  7
(a)(4)  of Form 8-K, such financial statements shall be filed  by
amendment  to this Form 8-K no later than 60 days after  May  22,
1998.

     (b)  Pro Forma Financial Information.

     As of the date of filing of this Current Report on Form 8-K,
it  is  impracticable for the Registrant to provide the pro forma
financial information required by this Item 7 (b).  In accordance
with  Item 7 (b) of Form 8-K, such financial statements shall  be
filed  by amendment to this Form 8-K no later than 60 days  after
May 22, 1998.

     (c)  Exhibits.

     2.1  Agreement for the sale and purchase of the issued share
capital  of Cox Investments Limited, dated April 30, 1998 between
Hoechst AG, Alpharma (U.K.) Limited, and Alpharma Inc.
                            
                            

                            
                            

                           SIGNATURES



     Pursuant to the requirements of the Securities Exchange  Act
of  1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.


                                   Alpharma Inc.


                                   By:   /s/   Jeffrey  E.  Smith
                                        Jeffrey E. Smith
                                        Executive Vice President
                                        Chief Financial Officer
Date:  May 22, 1998



                                                Page III
                                              CONFORMED COPY
                                                            
                                                            
                                                            
                                                            
                                                            
                                                            
                                                            
                                                            
                                                            
                     Dated 30 April 1998
                              
                              
                              
                              
                              
                              
                              
                              
                              
                         HOECHST AG
                              
                              
                              
                              
                              
                   ALPHARMA (U.K.) LIMITED
                              
                              
                              
                              
                              
                              
                              
                        ALPHARMA INC.
                              
                              
                              
                              
                              
                          AGREEMENT
              for the sale and purchase of the
                 issued share capital of Cox
                     Investments Limited
                              


                              
                              
                              
                          CONTENTS
                              
                              
Clause                                               Page

1.   1.   Definitions And Interpretation                4
2.   Sale of the Shares and Consideration    10
3.   Completion     11
4.   Net Asset Statement and Net Asset Adjustment 16
5.   Restrictions on Vendor   19
6.   Warranties     21
7.   Limitations On Claims    21
8.   Provisions relating to the use of the Cox Name    30
9.   Alpharma Guarantee, Vendor Indemnity and Confirmation
31
10.  Product Liability   32
11.  Entire agreement    33
12.  Variation 34
13.  Assignment     34
14.  Announcements  34
15.  Costs     35
16.  Invalidity     35
17.  Counterparts and Further Assurance 35
18.  Notices   35
19.  Governing Law And Jurisdiction     36
     SCHEDULE 1                                        38
     The Company And The Subsidiary 38
         SCHEDULE 2                         42
     Part A Warranties                      42
     Part B Tax Warranties                  53
     SCHEDULE 3   
     Properties                             57
     SCHEDULE 4                             59
   Specific Accounting Policies and Procedures to be used in
   preparing the Net Asset Statement                      59
   SCHEDULE 5                               60
   Tax Covenant                             60
   ANNEXURES                                79
   ANNEX A                                  79
   Transfer Agreement for NorCox Pharma AB  79
   ANNEX B                                  86
   Transfer Agreement for NorCox Pharma AS  86
   ANNEX C                                   93
   Transfer Agreement for Cox Pharma Belgium N.V. 93
   ANNEX D                                     13
   Transfer Agreement for NedCox Pharma B.V. 13
   
THIS SALE AND PURCHASE AGREEMENT is made on 30 April 1998

Between:

HOECHST  AKTIENGESELLSCHAFT a company  incorporated  in  and
under  the  laws of Germany with legal domicile  at  D-65926
Frankfurt  am Main, Germany and registered at the Commercial
Register  of the local court Frankfurt am Main Abteilung  B,
under registered number 14500 (the Vendor);

ALPHARMA  (U.K.) LIMITED (registered no. 3557686) a  company
incorporated  in  and under the laws of  England  and  Wales
whose  registered  office is at Whiddon Valley,  Barnstaple,
Devon EX32 8NS, England (the Purchaser); and

ALPHARMA  INC. a company incorporated in and under the  laws
of  Delaware  whose principal place of business  is  at  One
Executive Drive, Fort Lee, New Jersey 07024, USA (Alpharma).

Whereas:

(A)   Cox  Investments Limited (the Company)  is  a  private
company limited by shares incorporated in England and  Wales
on  6  June  1997  with registered number 3382754.   Further
details of the Company are set out in Part I of Schedule 1.

(B)   The Vendor has agreed to sell to the Purchaser for the
consideration  set out in clause 2.2 of this Agreement,  all
of  the issued shares in the capital of the Company upon the
terms  and  subject  to  the  conditions  set  out  in  this
Agreement,  together with all the issued  share  capital  in
each  of  NorCox  Pharma AB, NorCox Pharma  AS,  Cox  Pharma
Belgium N.V. and NedCox Pharma B.V. (the Overseas Companies)
upon the terms and subject to the conditions set out in  the
Transfer Agreements attached as Annexes A to D.

It Is Agreed as follows:

Definitions And Interpretation

1.1   In  this  Agreement, except  so  far  as  the  context
otherwise  requires,  the following  terms  shall  have  the
following meanings:

the  Accounts means in relation to either member of the  Cox
Group:

(a)  the audited balance sheet of the relevant company as at
     the Accounts Date; and
     
(b)  the  audited  profit and loss account of  the  relevant
     company in respect of the period ending on the Accounts
     Date,
     
together  with any notes, reports, statements  or  documents
permitted or required by the Companies Act 1985 to  be  made
thereon or annexed or attached thereto;

the Accounts Date means 31 December 1997;

Business  Day  means  a day (excluding Saturdays)  on  which
banks  generally are open in London for the  transaction  of
normal banking business;

Cash  means  the aggregate of all amounts under the  heading
"Cash at bank and in hand", as shown in the Accounts of  the
Subsidiary;

the Company has the meaning given in Recital (A);

Completion means completion of the sale and purchase of  the
Shares in accordance with clause 3;

the  Completion  Date   means the date on  which  Completion
occurs pursuant to clause 3;

Controlling  Interest  means (i) the  ownership  or  control
(directly  or indirectly) of more than fifty per cent  (50%)
of  the voting share capital of the relevant undertaking; or
(ii)  the  ability to direct the casting of more than  fifty
per  cent (50%) of the votes exercisable at general meetings
of  the  relevant undertaking on all, or substantially  all,
matters;  or (iii) the right to appoint or remove  directors
of the relevant undertaking holding a majority of the voting
rights  at  meetings of the board on all,  or  substantially
all, matters;

Coopers & Lybrand means Coopers & Lybrand of Midland  House,
Notte Street, Plymouth PL1 2EJ;

the Cox Group means the Company and the Subsidiary;

Cox   Group  Company  means  either  the  Company   or   the
Subsidiary;

Debt  means  all  amounts  under  the  heading  "Loans   and
Overdrafts",  as  shown in the Accounts of  the  Subsidiary,
including,  for  the  avoidance of  doubt,  any  Intra-Group
Indebtedness;

the   Disclosure  Letter  means  the  letter  of  even  date
herewith, in the form of the agreed draft, together with the
documents listed in the index attached thereto;

Generics  or Generic Products mean formulated pharmaceutical
products  made available for sale by the patent owner  prior
to  expiry of the patent thereon or by any other party after
expiry  of  the  patent, having first obtained  a  marketing
authorisation in respect thereof;

holding  company  shall  be  construed  in  accordance  with
sections 736 and 736A of the Companies Act 1985;

Intellectual Property Warranty means the warranty set out in
paragraph 16 of Part A of Schedule 2;

Intra-Group  Guarantees  means all guarantees,  indemnities,
counter-indemnities  and letters of comfort  of  any  nature
whatsoever:

(a)  given  to  any third party by any Cox Group Company  in
     respect  of  a liability of any member of the  Vendor's
     Group; and/or (as the context may require)
     
(b)  given  to any third party by any member of the Vendor's
     Group  in  respect  of a liability  of  any  Cox  Group
     Company;
     
Intra-Group Indebtedness means all debts outstanding between
members  of the Cox Group and members of the Vendor's  Group
(other than Intra-Group Trading Indebtedness);

Intra-Group Trading Indebtedness means all debts outstanding
between members of the Cox Group and members of the Vendor's
Group  in respect of intra-group trading activities  in  the
ordinary and usual course of business;

Midland  Bank Facility means the overdraft facility provided
to, inter alia, the Subsidiary by Midland Bank plc;

Midland Bank Guarantee means the guarantee dated 28 November
1996  in  respect  of  indebtedness  of,  inter  alia,   the
Subsidiary with Midland Bank plc;

Net  Assets  means  the aggregate of all amounts  under  the
headings  "Fixed  Assets"  and  "Current  assets"  less  the
aggregate  of all amounts under the headings "Provision  for
Liabilities  &  Charges" and "Creditors", as  shown  in  the
Accounts of the Subsidiary or in the Net Asset Statement, as
applicable;

Net Asset Statement means the statement of Net Assets as  at
the  close  of  business on Completion, to  be  prepared  in
accordance with clause 4 and Schedule 4;

Non-Trading  Companies means Thomas Marns  Limited,  Co-Tabs
(Overseas)  Limited, Dr Mackenzies Laboratories Limited  and
Cox Continental Limited;

the  Overseas Shares means the shares to be transferred from
the  Vendor  to  the  Purchaser  pursuant  to  the  Transfer
Agreements;

Overseas Warranties means the warranties on the part of  the
Vendor set out in the schedule to the Transfer Agreements;

Ownership  Warranties  means  the  warranties  set  out   in
paragraphs 2, 3, 4, 9(c) and 12(c) of Part A of Schedule 2;

the  Properties means any or all (or any part or  parts)  of
the  freehold and leasehold properties particulars of  which
are set out in Schedule 3;

Purchaser's  Accountants means Deloitte  &  Touche  or  such
other   internationally   recognised   firm   of   chartered
accountants  as the Purchaser may notify to  the  Vendor  in
writing;

Purchaser's Group means the Purchaser, any subsidiary of the
Purchaser,  any  holding company of the  Purchaser  and  any
subsidiary of such holding company from time to time;

Relevant Claim means any claim in respect of any breach of a
Warranty   or  any  claim  under  any  indemnity  given   or
obligation assumed by the Vendor under this Agreement (other
than  claims with respect to the Vendor's obligations  under
Clauses  2.4 and 4), the Tax Covenant or any of the Transfer
Agreements or any claim by the Purchaser (or any  member  of
the  Purchaser's Group) pursuant to this Agreement, the  Tax
Covenant or any of the Transfer Agreements;

the  Schedules means Schedules 1 to 5 to this Agreement  and
Schedule shall be construed accordingly;

the Shares means all of the issued shares in the capital  of
the Company;

the  Subsidiary means Arthur H. Cox & Co., Limited,  further
details of which are set out in Part II of Schedule 1;

subsidiary and subsidiaries shall be construed in accordance
with sections 736 and 736A of the Companies Act 1985;

Swindon  Site  means the factory operated by Hoechst  Marion
Roussel located at Kingfisher Drive, Swindon, Wiltshire;

subsidiary undertaking shall be construed in accordance with
section 258 of the Companies Act 1985;

the Tax Covenant means the covenant set out in Schedule 5;

the  Taxes  Act means the Income and Corporation  Taxes  Act
1988;

the  Tax  Provision Warranty means the warranty set  out  in
paragraph 2.1 of Part B of Schedule 2;

the  Tax Warranties means the warranties on the part of  the
Vendor set out in Part B of Schedule 2;

Trade Mark Assignment means the trade mark assignment in the
agreed  form to be entered into between the Vendor  and  the
Purchaser (or such other member of the Purchaser's Group  as
the  Purchaser shall nominate) which assigns all  rights  of
the Vendor in the Cox name anywhere in the world;

the  Transfer  Agreements means each of  the  four  transfer
agreements  to  be  entered  into  between  the  Vendor  and
Purchaser substantially in the form attached as Annexes A to
D to this Agreement relating to the transfer from the Vendor
to the Purchaser of the Overseas Companies;

Transfer  Pricing  Warranty means the warranty  set  out  in
paragraph 8 of part B of Schedule 2;

undertaking   shall   be  construed   in   accordance   with
section 259 of the Companies Act 1985;

Vendor's  Group  means  the Vendor, any  subsidiary  of  the
Vendor, any holding company of the Vendor and any subsidiary
of such holding company from time to time;

Vendor's Solicitors means Freshfields, Whitefriars, 65 Fleet
Street, London EC4Y 1HS;

the  Warranties  means the warranties on  the  part  of  the
Vendor  set  out  in Schedule 2 together with  the  Overseas
Warranties, and Warranty shall be construed accordingly.

1.2    In  this  Agreement,  unless  the  context  otherwise
requires:

(a)  words denoting any gender shall include all genders;
     
(b)  words  denoting the singular shall include  the  plural
     and vice versa;
     
(c)  references  to  persons or undertakings  shall  include
     individuals,  bodies corporate (wherever incorporated),
     unincorporated  associations,  partnerships  and  other
     unincorporated bodies (in each case, wherever  resident
     and for whatever purpose);
     
(d)  the  headings  are  inserted for convenience  only  and
     shall not affect the construction of this Agreement;
     
(e)  references  to  Recitals,  clauses  and  Schedules  and
     sub-divisions thereof are to the Recitals  and  clauses
     of  and  Schedules to this Agreement and  sub-divisions
     thereof respectively;
     
(f)  any  reference to an enactment is a reference to it  as
     from  time  to time amended, consolidated or re-enacted
     (with   or  without  modification)  and  includes   all
     instruments or orders made thereunder;
     
(g)  any  reference to a document "in the form of the agreed
     draft"  is to the form of the relevant document  agreed
     between   the   parties  and   for   the   purpose   of
     identification initialled by each of them or  on  their
     behalf;
     
(h)  any  statement qualified by the expression "so  far  as
     the Vendor is aware" or any similar expression shall be
     deemed  to  include  an additional statement  that  the
     statement has been made after reasonable enquiry of the
     directors of the Subsidiary.
     
1.3   The  Recitals and Schedules hereto form part  of  this
Agreement  and shall have the same force and  effect  as  if
expressly   set   out  in  the  body  of   this   Agreement.
Accordingly, any reference to "this Agreement" shall include
the Recitals and Schedules hereto.

1.4  The Disclosure Letter has such contractual effect as is
expressly  provided herein (or therein) but  does  not  form
part of this Agreement.

Sale of the Shares and Consideration

2.1   The  Vendor  hereby agrees to sell  and  transfer  (or
procure to be transferred) with full title guarantee and the
Purchaser  hereby agrees to purchase the Shares  as  at  and
with  effect from Completion, free from all charges,  liens,
encumbrances, equities, claims or other third  party  rights
(including,  without limitation, rights of  pre-emption)  of
any  nature whatsoever, together with all rights  which  now
are,  or at any time hereafter may become, attached to  them
(including,  without limitation, the right  to  receive  all
dividends and other distributions declared, made or paid  on
or after Completion).

2.2  The consideration for the sale of the Shares and for
the transfer of the Overseas Shares (the Purchase Price)
shall be the aggregate of:

(a)  the  Preliminary Purchase Price (as defined  in  clause
     2.3); and
     
(b)  an amount equal to the Net Assets, as stated in the Net
     Asset Statement, less BP13,662,000.
     
2.3    The   preliminary  purchase  price  (the  Preliminary
Purchase Price) to be paid by the Purchaser to the Vendor in
cash at Completion shall be BP114,848,000.

2.4   If,  following  the determination  of  the  Net  Asset
Statement pursuant to clause 4:

(a)  the  Purchase  Price  is higher  than  the  Preliminary
     Purchase  Price, the Purchaser shall pay to the  Vendor
     an  amount  equal to the amount by which  the  Purchase
     Price exceeds the Preliminary Purchase Price; or
     
(b)  the  Preliminary  Purchase Price  is  higher  than  the
     Purchase  Price, the Vendor shall pay to the  Purchaser
     an  amount equal to the amount by which the Preliminary
     Purchase Price exceeds the Purchase Price.
     
2.5   Any such amount to be paid by either the Purchaser  or
the Vendor pursuant to clause 2.4 shall be paid within seven
Business  Days  of  the  determination  of  the  Net   Asset
Statement pursuant to clause 4.

2.6   If  any payment is made by the Vendor to the Purchaser
pursuant to a claim made by the Purchaser for any breach  of
this  Agreement (including, without limitation, any Relevant
Claim), the payment shall so far as possible be made by  way
of  reduction of the consideration paid for the  Shares  and
that  consideration shall accordingly be deemed to have been
reduced by the amount of such payment.

Completion

3.1   The sale and purchase of the Shares shall be completed
at  the offices of the Vendor's Solicitors or at such  other
venue as may be agreed in writing between the Vendor and the
Purchaser,  at  10.00am on Thursday 7 May 1998  or  at  such
other  time and/or date as may be agreed in writing  between
the  Vendor and the Purchaser when the events set out in the
following provisions of this clause 3 shall take place.

3.2   The  Vendor shall deliver or cause to be delivered  to
the Purchaser:

(a)  duly  executed transfers into the name of the Purchaser
     or  its nominee in respect of the Shares, together with
     the relative share certificates;
     
(b)  share  certificates in respect of  all  of  the  issued
     shares in the capital of the Subsidiary;
     
(c)  the  Certificates of Incorporation, the  Common  Seals,
     all minute books, Share Registers and Share Certificate
     Books  (with any unissued share certificates) and other
     statutory books of each Cox Group Company;
     
(d)  directions,  in  the form of the agreed draft,  varying
     and/or  replacing the mandates given to the bankers  of
     each Cox Group Company;
     
(e)  evidence reasonably satisfactory to the Purchaser  that
     the  Vendor  is authorised to execute and  perform  its
     obligations under this Agreement and each of the  other
     documents to be executed by the Vendor pursuant hereto;
     
(f)  duly  executed counterparts of the Transfer  Agreements
     and the Trade Mark Assignment; and
     
(g)  evidence reasonably satisfactory to the Purchaser  that
     the Vendor has complied with its obligation pursuant to
     Clause 3.10.
     
3.3  The Purchaser shall:

(a)  in  satisfaction of its obligations under  clause  2.3,
     cause  the  Preliminary Purchase Price to  be  paid  by
     electronic funds transfer to the Vendor's bank  account
     at Deutsche Bank AG, London Branch, Account No: 203363;
     
(b)  deliver  to the Vendor evidence reasonably satisfactory
     to  the Vendor that the Purchaser and Alpharma are each
     authorised  to  execute  and perform  their  respective
     obligations under this Agreement and each of the  other
     documents  to  be  executed  by  the  Purchaser  and/or
     Alpharma, as applicable, pursuant hereto; and
     
(c)  deliver to the Vendor duly executed counterparts of the
     Transfer Agreements and the Trade Mark Assignment.
     
3.4   The  Vendor  shall  procure  that  a  meeting  of  the
directors  of  the  Company is held at which  the  following
business is transacted:

(a)  the   directors  of  the  Company  shall  approve   for
     registration  (subject  to  being  duly  stamped)   the
     transfers referred to in clause 3.2(a);
     
(b)  Peter   Loscher  and  Heinz  Zulauf  shall  resign   as
     directors  of the Company and shall sign as  a  deed  a
     letter  in  the form of the agreed draft and  Ingrid  B
     Wiik  and  Carl  - Ake Carlsson shall be  appointed  as
     directors  of  the Company, in each case,  with  effect
     from Completion;
     
(c)  Heinz  Zulauf shall resign as secretary of the  Company
     and  shall sign as a deed a letter in the form  of  the
     agreed draft and Charles Crosthwaite shall be appointed
     as secretary of the Company.
     
3.5   The  Vendor  shall  procure  that  a  meeting  of  the
directors of the Subsidiary is held at which Dr Peter Robert
Read  shall resign as a director of the Subsidiary and shall
sign as a deed a letter in the form of the agreed draft  and
Ingrid B Wiik and Carl-Ake Carlsson shall be appointed as  a
director  of the Subsidiary, in each case, with effect  from
Completion.

3.6  The Tax Covenant shall come into full force and effect.

3.7  [Deliberately omitted].

3.8   Following  Completion, the Vendor  undertakes  to  the
Purchaser  to  use all reasonable endeavours to  obtain  the
release  of  each  Cox  Group Company from  any  Intra-Group
Guarantees (including, without limitation, the Midland  Bank
Guarantee,  subject always to the members of the Purchaser's
Group  and the Cox Group Companies having complied with  all
their  obligations thereunder and carried  out  all  actions
which they are required to carry out (including repayment of
all amounts outstanding under the Midland Bank Facility)  to
enable the Vendor to obtain the release thereof) to which it
is  a  party  and,  pending such release, to  indemnify  the
relevant Cox Group Company against all amounts paid by it to
any  third  party pursuant to any such Intra-Group Guarantee
in  respect  of any liability of any member of the  Vendor's
Group whether arising before or after Completion.

3.9   Following Completion, the Purchaser undertakes to  the
Vendor  to  use  all  reasonable endeavours  to  obtain  the
release  of  each  member  of the Vendor's  Group  from  any
Intra-Group  Guarantees to which it is a party and,  pending
such  release,  to  indemnify the  relevant  member  of  the
Vendor's  Group against all amounts paid by it to any  third
party  pursuant to any Intra-Group Guarantees in respect  of
any  liability  of  any  Cox Group Company  whether  arising
before or after Completion.

3.10  The  Vendor  hereby  undertakes  to  waive,  prior  to
Completion,  the  dividend  of BP3,000,000  declared  by  the
Company  to  it  in respect of the financial year  ended  31
December   1997  and  to  procure  the  waiver,   prior   to
Completion,  of the dividend of BP3,000,000 declared  by  the
Subsidiary  in  favour of the Company  in  respect  of  such
financial year.

3.11.1    Pending Completion, the Vendor shall ensure that:

(a)  other   than   as  required  to  fulfil  the   Vendor's
     obligations  pursuant to Clause  3.10  each  Cox  Group
     Company shall carry on its business in the ordinary and
     usual course and shall not make (or agree to make)  any
     payment other than routine payments in the ordinary and
     usual course of trading;
     
(b)  no  dividend or other distribution (within the  meaning
     of  section  209 of the Taxes Act) shall  be  declared,
     paid or made by any Cox Group Company;
     
(c)  no share or loan capital shall be allotted or issued or
     agreed  to  be  allotted or issued  by  any  Cox  Group
     Company;
     
(d)  no  variation is made to any existing contract  between
     either Cox Group Company and any member of the Vendor's
     Group and no such contract is entered into; and
     
(e)  no  Cox Group Company resolves to change its name or to
     alter its Memorandum or Articles of Association.
     
3.11.2      Pending   Completion,  the  Vendor   shall   use
reasonable endeavours to ensure that the Purchaser is  given
reasonable  supervised  access  to  David  Green  and  Peter
Grinstead  and  is provided with any information  which  the
Purchaser reasonably requests.

3.12  The  Purchaser shall procure that, as soon as possible
following Completion, offers of employment are made  to  Mr.
Jef  Hus,  Mlle Kalija Badli and Mlle Laurance  Lemaitre  on
terms  no  less favourable than those currently  enjoyed  by
such persons, including with regard to length of service.

3.13  In  the  event  that Bjorn Lindahl is  made  redundant
following Completion the parties hereby agree that the costs
of  any  such redundancy (if any) shall be borne equally  by
the  parties and the Purchaser hereby undertakes to pay  the
amount  due from it to the Purchaser pursuant to this Clause
3.13  within seven (7) days of the Vendor delivering to  the
Purchaser a written request therefor.

3.14   The   Vendor   undertakes  to  the  Purchaser   after
Completion:

(i)  in  the event that any member of the Vendor's Group  or
     their  past or present advisers discovers any  material
     (including  copy  material) relating to  the  statutory
     books and records or corporate good standing of the Non-
     Trading Companies, to procure that such member delivers
     such material to the Purchaser or as it may direct in a
     timely manner; and
     
(ii) to  use  its reasonable endeavours to procure that,  at
     the  reasonable  request of, and at the  cost  of,  the
     Purchaser, any relevant member of the Vendor's Group or
     employee  thereof shall take such action, execute  such
     documents  and  provide such information  as  they  are
     capable  of taking, executing or providing in order  to
     assist    the   Purchaser   or   the   Subsidiary    in
     reconstituting the statutory books and records  of  the
     Non-Trading  Companies,  securing  the  corporate  good
     standing  of the Non-Trading Companies or in  arranging
     for  the Non-Trading Companies to be struck off by  the
     Registrar of Companies.
     
3.15  Prior to Completion, the Vendor undertakes to  procure
that  the relevant member of the Vendor's Group will confirm
in   writing  that  it  will  not  exercise  any  right   of
termination under the contracts set out in Clause 3.16 which
it  may have as a result of the acquisition of the Shares by
the Purchaser.

3.16 The contracts referred to in Clause 3 are as follows:

          (i)  the contract relating to the distribution  of
          Aspav  between  the Subsidiary  and  the  relevant
          member of the Vendor's Group;
          
          (ii) the contract relating to the distribution  of
          Cyclogest between the Subsidiary and the  relevant
          member of the Vendor's Group; and
          
          (iii)     the contract relating to packing, at the
          Swindon  Site,  between  the  Subsidiary  and  the
          relevant   member  of  the  Vendor's  Group   (the
          Packaging Contract).
          
3.17 The Vendor hereby confirms that the initial term of the
Packaging Contract will not, otherwise than in circumstances
where  such  Contract is duly terminated in accordance  with
its terms, expire prior to 31 December 1999.

Net Asset Statement and Net Asset Adjustment

4.1   The  Vendor and the Purchaser shall use all reasonable
endeavours  to procure that, promptly after Completion,  the
Net  Asset  Statement  is prepared in  accordance  with  the
provisions of this clause 4.  Such Net Asset Statement  will
be prepared on the basis set out in Schedule 4.

4.2  Following Completion, the Vendor shall instruct Coopers
&  Lybrand  to prepare a draft Net Asset Statement  and  the
Purchaser shall make all necessary arrangements with Coopers
&  Lybrand  with  a  view to Coopers & Lybrand  being  in  a
position  to deliver such draft Net Asset Statement  to  the
Purchaser  (with  a  copy  to the  Purchaser's  Accountants)
within 30 days of Completion.

4.3  The Purchaser shall notify the Vendor within 20 days of
receipt of such draft Net Asset Statement whether or not  it
accepts it for the purposes of this Agreement.

4.4   If the Purchaser notifies the Vendor that it does  not
accept such draft Net Asset Statement:

(a)  it  shall  set  out its reasons for such non-acceptance
     and  specify  the  adjustments which, in  its  opinion,
     should  be  made  to the draft Net Asset  Statement  in
     order   to  comply  with  the  requirements   of   this
     Agreement; and
     
(b)  the  parties  shall use all reasonable  endeavours  (in
     conjunction   with  the  Purchaser's  Accountants   and
     Coopers  &  Lybrand) to meet and discuss the objections
     of  the  Purchaser  and  to reach  agreement  upon  the
     adjustments (if any) required to be made to  the  draft
     Net Asset Statement.
     
4.5   If the Purchaser is satisfied with the draft Net Asset
Statement   (either   as  originally  submitted   or   after
adjustments agreed between the Purchaser and the Vendor)  or
if   the  Purchaser  fails  to  notify  the  Vendor  of  its
non-acceptance of the draft Net Asset Statement  within  the
20  day period referred to in clause 4.3, then the draft Net
Asset Statement (incorporating any agreed adjustments) shall
constitute the Net Asset Statement for the purposes of  this
Agreement.

4.6   If the Purchaser and the Vendor do not reach agreement
within  30  days of the Purchaser's notice of non-acceptance
under  clause  4.4,  then the matters in  dispute  shall  be
referred,   on   the  application  of  either   party,   for
determination  by  an  independent firm  of  internationally
recognised  chartered accountants to be agreed upon  by  the
Purchaser and the Vendor or, failing such agreement,  to  be
selected  by  the  President  for  the  time  being  of  the
Institute  of  Chartered Accountants in England  and  Wales.
The following terms of reference shall apply:

(a)  the  Purchaser's Accountant and Coopers & Lybrand shall
     each  promptly  prepare  a  written  statement  of  the
     matters  in  dispute which (together with the  relevant
     documents) shall be submitted to such independent  firm
     for determination;
     
(b)  in giving such determination, the firm shall state what
     adjustments  (if any) are necessary to  the  draft  Net
     Asset Statement in respect of the matters in dispute in
     order   to  comply  with  the  requirements   of   this
     Agreement;
     
(c)  such  firm  shall  act  as an expert  (and  not  as  an
     arbitrator)  in  making  any such  determination  which
     shall be final and binding on the parties;
     
(d)  the   expenses   of  any  such  determination   by   an
     independent firm of accountants shall be borne  between
     the Vendor and the Purchaser in such proportions as the
     firm  shall  in its discretion determine  and,  in  the
     absence  of  determination, equally by the  Vendor  and
     Purchaser.
     
4.7   If the Vendor and the Purchaser reach (or pursuant  to
clause  4.5 are deemed to reach) agreement on the Net  Asset
Statement  or the Net Asset Statement is finally  determined
at any stage in the procedure set out in this clause 4:

(a)  the  Net  Asset  Statement as so agreed  or  determined
     shall  be  the Net Asset Statement for the purposes  of
     this  Agreement and shall be final and binding  on  the
     parties; and
     
(b)  the  amount of the Net Assets shall be derived from the
     Net Asset Statement.
     
4.8   The  Purchaser shall use all reasonable endeavours  to
ensure  that the Subsidiary provides Coopers & Lybrand  with
such  access to the employees, accounts, working papers  and
other   financial  information  of  the  Subsidiary  as   is
reasonably  necessary for the purposes  of  this  Agreement.
Each party shall similarly use all reasonable endeavours  to
ensure  that  the  Purchaser's  Accountants  and  Coopers  &
Lybrand  each have such access to all relevant  working  and
other papers of the other as is reasonably necessary for the
purposes of this Agreement.

Restrictions on Vendor

5.1   The Vendor shall not and shall procure that each other
member  of  the Vendor's Group shall not (whether  alone  or
jointly  with  another and whether directly  or  indirectly)
carry  on  or  be  engaged or interested  in  any  Competing
Business  during a period of 18 months after the  Completion
Date.   For  this  purpose,  Competing  Business  means  the
manufacture  and/or  sale  of Generic  Products  within  the
United Kingdom.

5.2   The  restriction  contained in clause  5.1  shall  not
affect or prohibit:

(a)  the  acquisition  or  holding  by  any  member  of  the
     Vendor's  Group of shares amounting to less than  three
     per cent (3%) of the capital of a company quoted on any
     stock exchange engaged in a Competing Business; or
     
(b)  the  acquisition  or  holding  by  any  member  of  the
     Vendor's  Group of a Controlling Interest in a  company
     or undertaking engaged in a Competing Business provided
     that the annual turnover of the activities constituting
     the Competing Business amounts to less than twenty-five
     per  cent  (25%)  of the turnover of  such  company  or
     undertaking as a whole.
     
5.3   The  provisions  of this clause 5  shall  not  prevent
members of the Vendor's Group:

(a)  manufacturing  and/or  selling  Generic   Products   in
     respect  of  which a member of the Vendor's Group  owns
     the relevant patent;
     
(b)  manufacturing and/or selling Generic Products which are
     manufactured  and/or  sold by them  at  the  Completion
     Date;
     
(c)  manufacturing  Generics  on  behalf  of   third   party
     companies at the Swindon Site;
     
(d)  manufacturing  at  the  Swindon  Site  and/or   selling
     Generics    of    hospital   pharmaceutical    products
     manufactured  at  the Swindon Site on behalf  of  third
     party companies.
     
5.4  The Vendor shall not (and shall procure that each other
member  of the Vendor's Group shall not) within a period  of
12 months after the Completion Date, directly or indirectly,
solicit  or endeavour to entice away from either  Cox  Group
Company  any  person who was employed by  either  Cox  Group
Company in skilled or managerial work at any time during the
12 months prior to the Completion Date.

5.5   Except  so  far  as may be required  by  law,  in  the
circumstances  and  only after prior consultation  with  the
Purchaser, the Vendor shall not (and shall procure that each
other  member of the Vendor's Group shall not) for a  period
of  five  years after Completion disclose to any person  any
trade  secret  or  other  confidential  information   of   a
technical character which it holds in relation to either Cox
Group Company, provided that this obligation shall not apply
to any information which:

(a)  is publicly available;
     
(b)  does  not  relate  to the manufacture of  any  specific
     product  and was in the possession of a member  of  the
     Vendor's Group prior to or at the date hereof; or
     
(c)  becomes  available  to a member of the  Vendor's  Group
     from  a  third  party otherwise than in breach  of  any
     obligation  of  confidentiality owed  as  at  the  date
     hereof by such third party to either Cox Group Company.
     
5.6  The Vendor acknowledges and agrees that each of clauses
5.1,  5.2, 5.3, 5.4 and 5.5 constitutes an entirely separate
and  independent  restriction and that the duration,  extent
and  application of each restriction are no greater than  is
reasonable and necessary for the protection of the interests
of the Purchaser.

Warranties

6.1   The  Vendor warrants to the Purchaser in the terms  of
the  Warranties  (other than the Overseas  Warranties)  with
effect  as  at, and speaking to events, facts,  matters  and
circumstances in existence as at, 30 April 1998 subject to:

(a)  any  matter  disclosed  in the  Disclosure  Letter  (or
     treated  by  the Disclosure Letter as being disclosed),
     the  draft Coopers & Lybrand Long Form Report dated  23
     February  1998, the Actuarial Valuation of the  Pension
     Schemes  (defined at paragraph 15 of Part A of Schedule
     2)  as  at  1 October 1996 dated 13 June 1997  and  the
     Environmental Report of W S Atkins Consultants  Limited
     dated 19 February 1998); and
     
(b)  the limitations and qualifications set out in Clause 7.
     
6.2  Save to the extent that a particular Warranty expressly
states  otherwise,  the Vendor makes  no  representation  or
warranty  to the Purchaser as to the completeness, truth  or
accuracy of the matters disclosed in the Disclosure Letter.

6.3  Only Warranty 9 shall apply to the Properties.

Limitations On Claims

7.1   The provisions of this clause 7 shall operate to limit
or  reduce  the  liability of the Vendor in respect  of  any
Relevant Claim.

7.2.1      The  Vendor shall not be liable for any  Relevant
Claim  (other than a claim pursuant to Clause 10) unless  it
shall  have  received  from  the  Purchaser  written  notice
containing  details  of the Relevant  Claim,  including  the
Purchaser's reasonable estimate of the amount thereof:

(i)  in  the  case  of a Relevant Claim, not being  a  claim
     pursuant  to the Tax Covenant or a claim for breach  of
     the  Transfer Pricing Warranty or for breach of the Tax
     Provision Warranty by virtue of an adjustment  pursuant
     to  section  770(3) of the Taxes Act, on or before  the
     first anniversary of the Completion Date;
     
(ii) in  the  case of a Relevant Claim pursuant to  the  Tax
     Covenant or a claim for breach of the Transfer  Pricing
     Warranty or for breach of the Tax Provision Warranty by
     virtue  of an adjustment pursuant to section 770(3)  of
     the  Taxes  Act, on or before the date which  is  three
     calendar  months  after the end of the sixth  financial
     year ending after Completion.
     
7.2.2      The  Vendor  shall not  be  liable  for  a  claim
pursuant to Clause 10 unless it shall have received from the
Purchaser  written notice containing details of  the  claim,
including  the  Purchaser's written estimate thereof  on  or
before 30 April 2008.

7.3   Any  Relevant  Claim (other than a claim  pursuant  to
Clause  10)  shall (if it has not been previously satisfied,
settled  or  withdrawn)  be deemed to  have  been  withdrawn
unless  legal  proceedings  in  respect  of  it  have   been
commenced by both being issued and served within 9 months of
notification to the Vendor pursuant to clause 7.2.

7.4   If  the Purchaser becomes aware of any Relevant Claim,
potential  Relevant Claim, matter or event which might  lead
to a Relevant Claim being made, the Purchaser shall promptly
give  notice thereof to the Vendor and, as regards any  such
Relevant  Claim, potential Relevant Claim, matter or  event,
the  Purchaser  shall not make any admission  of  liability,
agreement  or compromise with any person, body or  authority
in  relation thereto without prior consultation with and the
prior written agreement of the Vendor and shall take (or, as
appropriate,  procure  that the Company  or  the  Subsidiary
shall take) such action as the Vendor may reasonably request
to  avoid, dispute, resist, appeal, compromise or defend the
Relevant Claim, potential Relevant Claim, matter or event or
any  adjudication  in respect thereof, but  subject  to  the
Purchaser  being  fully  indemnified  and  secured  to   its
reasonable satisfaction by the Vendor against all reasonable
out-of-pocket  costs and expenses incurred by the  Purchaser
or  any  Cox Group Company consequently arising.  The action
which   the   Vendor  may  reasonably  request  under   this
clause 7.4 shall include (without limitation):

(i)  the  Purchaser  allowing, or, as  appropriate,  procure
     that  the Company or the Subsidiary allows, the  Vendor
     to  take  on  or take over (on the costs  and  expenses
     basis  referred  to  in  the  preceding  sentence)  the
     conduct  of  all  proceedings  and/or  negotiations  of
     whatsoever  nature  arising  in  connection  with   the
     Relevant  Claim,  potential Relevant Claim,  matter  or
     event in question; or, (at the Vendor's discretion),
     
(ii) the Purchaser assigning or procuring the assignment  to
     the  Vendor (or as the Vendor may direct) of any rights
     of action which the Purchaser, either Cox Group Company
     or  any other company in the Purchaser's Group may have
     against  any  third party in respect  of  the  Relevant
     Claim,  potential Relevant Claim, matter  or  event  in
     question.
     
If  the  Vendor  takes  on  or takes  over  the  conduct  of
proceedings and/or negotiations:

(a)  the Purchaser shall, on the basis that the Vendor shall
     fully  indemnify  the Purchaser and  the  relevant  Cox
     Group  Company  against  all  reasonable  out-of-pocket
     costs  and expenses consequently arising, provide  (or,
     as  appropriate,  procure that such Cox  Group  Company
     provides) such information and assistance as the Vendor
     may   reasonably   require  in  connection   with   the
     preparation for and conduct of such proceedings  and/or
     negotiations;
     
(b)  (subject  to  the  Purchaser having complied  with  the
     relevant  requirements set out in the above  provisions
     of this clause 7.4) the Vendor shall keep the Purchaser
     informed  of proposed meetings with any relevant  third
     party,  allow  an observer appointed on behalf  of  the
     Purchaser  or either Cox Group Company to  attend  such
     meetings  and  advise the Purchaser of the  outcome  of
     meetings and discussions to which any such observer was
     not a party or at which he was not present;
     
(c)  where,  in  relation to a Relevant Claim to which  this
     clause  7.4  applies, the Vendor is able  to  secure  a
     potential settlement for the relevant Cox Group Company
     with  a relevant third party at an amount which is less
     than  Lier50,000 in respect of the loss in such Cox  Group
     Company in respect of which the Relevant Claim is  made
     it  shall notify the Purchaser which shall then  either
     (i) agree to that settlement (in which event the Vendor
     shall be released from all liability in respect of such
     Relevant Claim and any other Relevant Claim in  respect
     of  the same subject matter) or (ii) elect to take over
     negotiations  with the relevant third  party  in  which
     case  the Purchaser shall release (and provide  written
     confirmation  of such release to) the Vendor  from  all
     liability  in respect of such Relevant Claim  (and  any
     other  Relevant Claim which can be made in  respect  of
     the  same  subject matter).  If the Purchaser  has  not
     notified  the Vendor of its decision within 3  business
     days  of  being notified of the proposed settlement  it
     shall  be  deemed to have elected to agree the proposed
     settlement.
     
Except with the prior consent of the Purchaser (such consent
not  to be unreasonably withheld) the Vendor shall not where
it  has  assumed  control of negotiations or proceedings  in
respect  of third party claims under the provisions of  this
clause  7.4, settle or compromise any such claim on a  basis
which  results  in  a  net  increase  in  either  Cox  Group
Company's  tax  or  other liabilities elsewhere  unless  the
Vendor  fully indemnifies such Cox Group Company in  respect
of  such  net  increase and in pursuing any such  claim  the
Vendor shall (so far as reasonably consistent with achieving
a  successful  outcome in respect of  the  claim)  have  due
regard  to any continuing relationship the Cox Group Company
in  question  may have with the relevant third party.   Upon
the  Vendor  agreeing any settlement with a third  party  in
relation to any third party claim as referred to above,  the
Vendor  shall  (to  the extent that it is liable  under  the
provisions  of this Agreement in respect of the  payment  of
any   part  of  the  settlement  amount)  promptly  put  the
Purchaser in funds in respect of that part at the same  time
as  the  Purchaser or, as the case may be, the relevant  Cox
Group  Company  is  required to  make  due  payment  of  the
settlement  amount to the third party bearing  in  mind  any
available credit period.

For the avoidance of doubt, nothing in this clause 7.4 shall
in  any way restrict or limit the general obligation at  law
of  each  of  the Purchaser and either Cox Group Company  to
mitigate  any  loss  or  damage  which  it  may  suffer   in
consequence of any breach by the Vendor of the terms of this
Agreement,  provided that in respect of such  obligation  to
mitigate  the Purchaser shall not, in the case  of  a  claim
pursuant  to  Clause 10 only, be obliged to make  any  claim
under  any policy of insurance maintained by the Purchaser's
Group in respect of Product Liability Claims (as defined  in
Clause 10).

7.5   The Vendor shall have no liability in respect  of  any
Relevant Claim unless the liability of the Vendor in respect
of such claim exceeds BP50,000 in which case the Vendor shall
only  be liable for the excess.  For the avoidance of doubt,
amounts  for which the Vendor has no liability, or by  which
the  Vendor's liability is reduced, as a consequence of  the
operation  of  this  clause  7  shall  not  be  capable   of
constituting  a  Relevant  Claim or  increasing  the  amount
thereof for the purpose of this clause 7.5.

7.6.1     No liability shall attach to the Vendor in respect
of any Relevant Claim (other than a claim pursuant to Clause
10)  unless  the  aggregate amount of the liability  of  the
Vendor  to  the Purchaser in respect of all Relevant  Claims
(excluding for this purpose, any claim(s) pursuant to Clause
10) shall exceed BP1,250,000, in which event the Vendor shall
be  liable (subject always to the other provisions  of  this
clause 7) for the entire amount and not just the excess over
BP1,250,000.   For  the avoidance of any doubt,  amounts  for
which  the Vendor has no liability, or by which the Vendor's
liability  is reduced, as a consequence of the operation  of
this clause 7 shall not be capable of being aggregated as  a
Relevant  Claim  or part thereof with other Relevant  Claims
for the purposes of this clause 7.6.1.

7.6.2     No liability shall attach to the Vendor in respect
of  any  claim  pursuant to Clause 10 unless  the  aggregate
amount  of  the liability of the Vendor to the Purchaser  in
respect  of  all claims pursuant to Clause 10  shall  exceed
BP1,250,000,  in  which  event the  Vendor  shall  be  liable
(subject always to the other applicable provisions  of  this
clause 7) for the entire amount and not just the excess over
BP1,250,000.   For  the avoidance of any doubt,  amounts  for
which  the Vendor has no liability, or by which the Vendor's
liability  is reduced, as a consequence of the operation  of
this clause 7 shall not be capable of being aggregated as  a
claim  pursuant  to  Clause 10 or part  thereof  with  other
claims  pursuant  to  Clause 10 for  the  purposes  of  this
clause 7.6.2.

7.7   The total aggregate liability of the Vendor in respect
of  all Relevant Claims shall not exceed 50 per cent. of the
Purchase  Price, save that the total aggregate liability  of
the  Vendor shall be increased to, but shall, in  no  event,
exceed 100 per cent. of the Purchase Price:

(i)  in  respect  of  a  claim for  breach  of  any  of  the
     Ownership Warranties; and
     
(ii) where   it  is  determined  by  a  court  of  competent
     jurisdiction  that  the Vendor has been  fraudulent  in
     producing the Disclosure Letter.
     
7.8   The Vendor shall not be liable for any Relevant  Claim
(other than a claim pursuant to Clause 10) in respect of any
matter to the extent that:

(a)  allowance, provision or reserve has been made for  such
     matter in the Accounts or to the extent that payment or
     discharge  of the relevant matter has been  taken  into
     account therein;
     
(b)  such  Relevant  Claim  arises or, such  Relevant  Claim
     otherwise  having arisen, is increased as a  result  of
     any  change  made  after  the Completion  Date  in  any
     accounting or taxation policies or practice  of  either
     Cox Group Company, the Purchaser or any other member of
     the Purchaser's Group.
     
7.9   Where a Cox Group Company or the Purchaser is entitled
(whether  by  reason of insurance (in the case of  insurance
only,  other than in the case of a claim pursuant to  Clause
10)  or payment discount or otherwise) to recover from  some
other  person  any sum in respect of taxation or  any  other
liability,  loss or damage the subject of a  Relevant  Claim
against  the Vendor or for which a Relevant Claim  could  be
made  (and  whether  before or after  the  Vendor  has  made
payment hereunder), the Purchaser shall promptly notify  the
Vendor  and  provide  such information  as  it  may  require
relating to such liability or dispute and the steps taken or
to  be  taken  by  the Purchaser or the relevant  Cox  Group
Company  in  connection with it and, if so required  by  the
Vendor  and  at  the Vendor's cost and expense  and  on  the
Vendor providing proper indemnities in respect of all  costs
and  expenses to be incurred, the Purchaser shall, and shall
procure  that  the relevant Cox Group Company shall,  before
seeking  to  recover any amount from the Vendor  under  this
Agreement or the Tax Covenant, first take all steps (whether
by  way  of  a  claim  against its  insurers  or  otherwise)
including, but without limitation, proceedings as the Vendor
may  reasonably require to enforce such recovery  and  shall
keep the Vendor informed of the progress of any action taken
and thereafter any claim against the Vendor shall be limited
(in  addition  to  the limitations on the liability  of  the
Vendor  referred to in this Clause) to the amount  by  which
the loss or damage suffered by the Purchaser as a result  of
such breach shall exceed the amount so recovered.

7.10  If  the  Vendor  pays to the Purchaser  an  amount  in
discharge  of a Relevant Claim and the Purchaser  or  either
Cox Group Company subsequently recovers (whether by payment,
discount,  credit, relief or otherwise) from a  third  party
(including any taxation authority) a sum which is  referable
to   the  Relevant  Claim,  the  Purchaser  shall  (or,   as
appropriate,  shall  procure that  such  Cox  Group  Company
shall) forthwith repay to the Vendor:

(a)  an  amount  equal to the sum recovered from  the  third
     party  less  any  reasonable  out-of-pocket  costs  and
     expenses  incurred by the Purchaser or  the  Cox  Group
     Company  in recovering the same and any tax payable  by
     the  Purchaser or the Cox Group Company in  respect  of
     the sum recovered; or
     
(b)  if  the  figure resulting under paragraph (a) above  is
     greater  than  the  amount paid by the  Vendor  to  the
     Purchaser or the relevant Cox Group Company in  respect
     of the such Relevant Claim, such lesser amount as shall
     have been so paid by the Vendor;
     
so  as  to  leave  the Purchaser (taking  into  account  the
amounts  received from the third party and from  the  Vendor
and  those  payable to the Vendor under this clause)  in  no
better or worse position than it would have been in (subject
always to the other provisions of this clause 7.10) had  the
Relevant Claim not arisen in the first place.

7.11  If  any Relevant Claim shall arise by reason  of  some
liability  which  at  the time that the  Relevant  Claim  is
notified to the Vendor is contingent only, the Vendor  shall
not  be  under  any obligation to make any  payment  to  the
Purchaser  thereunder  until such time  as  such  contingent
liability ceases to be so contingent.

7.12  The  Vendor  shall not be liable  in  respect  of  any
Relevant Claim (other than a claim pursuant to Clause 10) to
the  extent that the amount of such Relevant Claim would  be
recoverable  from  insurers  if the  policies  of  insurance
effected  by or for the benefit of either Cox Group  Company
were  maintained  on  no  less  favourable  terms  as  those
existing at the date hereof.

7.13  Upon  any  Relevant Claim being  made,  the  Purchaser
shall,  and shall co-operate to procure that each Cox  Group
Company  shall,  make  available to accountants  and  others
appointed   by   the  Vendor  such  relevant   records   and
information as the Vendor reasonably requests in  connection
with  such Relevant Claim (including the position under  the
provisions  contained  in clauses  7.8  and  7.10)  and  the
Purchaser  shall, and shall co-operate to procure that  each
Cox Group Company shall, use best endeavours to procure that
the  auditors (both past and then current) of the Cox  Group
make  available to the Vendor and to accountants and  others
appointed  by  the  Vendor  their audit  working  papers  in
respect  of  their  audit  of  either  Cox  Group  Company's
accounts  for  any relevant accounting period in  connection
with the Relevant Claim.

7.14  The Vendor shall not be liable for such Relevant Claim
if  and  to the extent it would not have arisen but for  any
act, omission or transaction carried out after Completion by
the  Purchaser  or  a Cox Group Company or their  respective
directors, employees or agents or before Completion  at  the
direction of the Purchaser.

7.15  The  Vendor  shall not be liable  in  respect  of  any
Relevant Claim (other than a claim pursuant to Clause 10) to
the  extent that such Relevant Claim is attributable to,  or
such Relevant Claim otherwise having arisen, is increased as
a  result of any legislation not in force at the date hereof
or   to   any  change  of  law  or  administrative  practice
(including but not limited to extra-statutory concessions of
the  Inland  Revenue)  which takes effect  retroactively  or
occurs  as a result of any increase in the rates of taxation
in  force at the date hereof or occurs as a result of or  is
otherwise  attributable  to the Purchaser  or  a  Cox  Group
Company  disclaiming any part of the benefit of  capital  or
other allowances against taxation claimed or proposed to  be
claimed on or before the date hereof.

7.16 The Warranties and the Tax Covenant shall be actionable
only  by  the Purchaser and no other party shall be entitled
to  make any claim or take any action whatsoever against the
Vendor  under or arising out of or in connection  with  this
Agreement or the Tax Covenant.

7.17  A  breach of the Warranties which is capable of remedy
shall  not entitle the Purchaser to compensation unless  the
Vendor  is  given  written notice of such  breach  and  such
breach  is  not remedied within 30 days after  the  date  on
which such notice is served on the Vendor.

7.18 The Purchaser hereby agrees for itself and on behalf of
each  Cox  Group Company with the Vendor that in respect  of
any  Relevant  Claim where the Vendor may be liable  to  the
Purchaser under the Warranties and which may also give  rise
to a liability under the Tax Covenant or in respect of which
the Purchaser is entitled to receive any amount pursuant  to
Clause  2.4, Clause 4 or Clause 10, the Vendor shall not  be
obliged  to  meet any such liability more  than  once.   Any
recovery  by  the Purchaser in respect of any such  Relevant
Claim  under the Warranties shall be deemed to be a recovery
by  all the relevant parties under the Tax Covenant and  any
recovery by any party under the Tax Covenant shall be deemed
to  be a recovery by the Purchaser under this Agreement  for
breach of the Warranties (as the case may be) and a recovery
by the Purchaser or either Cox Group Company shall be deemed
to be a recovery by each of them.

7.19  The  sole remedy against the Vendor for any breach  of
any of the Warranties, any other breach of this Agreement by
the  Vendor  or  any event giving rise to liability  on  the
Vendor under the Tax Covenant shall be an action for damages
and  the  Purchaser shall not be entitled  to  rescind  this
Agreement.

7.20  The  Vendor  shall not be liable  in  respect  of  any
Relevant Claim (other than a claim pursuant to Clause 10  or
the  Tax Covenant) where any member of the Purchaser's Group
as  at  the  date  hereof was aware  at  the  time  of  this
Agreement   being   entered  into  of  facts,   matters   or
circumstances  which are the subject of the  Relevant  Claim
and  any  such member of the Purchaser's Group was aware  at
such  time that those facts, matter or circumstances  would,
when  this  Agreement  was entered  into,  have  caused  the
relevant  Warranty or Warranties to be untrue or  inaccurate
or misleading.

7.21  Clauses 7.4, 7.8, 7.10, 7.14 and 7.15 above shall  not
apply  to  claims for breach of the Tax Warranties or  under
the Tax Covenant and, accordingly, paragraphs 3, 8 and 10 of
the  Tax  Covenant  shall  apply to  claims  under  the  Tax
Warranties  as they do in relation to claims under  the  Tax
Covenant.

Provisions relating to the use of the Cox Name

8.1   Without  prejudice to any right of  the  Purchaser  to
bring  a  claim  for  breach  of the  Intellectual  Property
Warranty,    the    Purchaser   hereby    irrevocably    and
unconditionally releases the Vendor (on its  behalf  and  on
trust  for  each  member of the Vendor's  Group)  from,  and
waives,  and  shall procure that each Cox Group Company  and
each  member of the Purchaser's Group shall irrevocably  and
unconditionally releases the Vendor (on its  behalf  and  on
trust  for  each  member  of the Vendor's  Group)  from  and
waives,  all claims (if any) arising from any use whatsoever
made  by  the members of the Vendor's Group of the Cox  name
and trade mark at any time prior to Completion.

8.2   The  Vendor hereby undertakes to cease, and to procure
that  each member of the Vendor's Group shall cease, to  use
the  Cox  name and trade mark as soon as possible  following
Completion and, in any event, prior to 1 March 1999.

Alpharma Guarantee, Vendor Indemnity and Confirmation

9.1  In consideration of the Vendor entering into and acting
in  accordance  with this Agreement, Alpharma (as  principal
obligor  and  not  merely as a surety)  unconditionally  and
irrevocably guarantees as a continuing obligation the proper
and  punctual  performance  by  the  Purchaser  of  all  its
obligations  under or pursuant to this Agreement  (including
any documents of transfer or otherwise entered into pursuant
to the terms of this Agreement).

9.2   Alpharma's liability hereunder shall not be discharged
or  impaired  by  any  amendment to  or  variation  of  this
Agreement,  any  release of, or granting of  time  or  other
indulgence  to,  the  Purchaser  or  any  third  party,  any
liquidation,  administration, receivership or winding-up  of
the  Purchaser or by any other act or omission or any  other
events or circumstances whatsoever (whether or not known  to
the  Vendor, the Purchaser or Alpharma) which would or might
(but  for  this  clause)  operate  to  impair  or  discharge
Alpharma's liability under this guarantee.

9.3   As  a  separate,  continuing and  primary  obligation,
Alpharma  undertakes  to  indemnify  the  Vendor  on  demand
against all losses, claims or costs suffered or incurred  by
the  Vendor   while acting in good faith should any  amounts
which  would  otherwise be due under this Agreement  not  be
recoverable  for  any reason whatsoever including  (but  not
limited  to) the Agreement being or becoming void,  voidable
or unenforceable.

9.4   Until  such  time  as the option granted  pursuant  to
Clause  9.7 has been exercised, the Vendor hereby  covenants
with  the  Purchaser  to indemnify and  keep  the  Purchaser
indemnified  on demand against all losses, claims  or  costs
suffered or incurred by any member of the Purchaser's  Group
as   a   direct  result  of  any  liability  of  any  nature
whatsoever, in existence on or prior to the date hereof, of,
within or affecting any of the Overseas Companies other than
a liability arising:

(i)  in  the ordinary course of the business of the relevant
     Overseas Company, save where such liability arises as a
     result of any non-trading indebtedness; and/or
     
(ii) arising,  or  referable  to, an event  occurring  after
     Completion.
     
9.5   To  the  extent that any Intra-Group  Indebtedness  is
found to be owing from any of the Overseas Companies to  any
other member of the Vendor's Group, the Vendor undertakes to
procure that the relevant member of the Vendor's Group shall
waive the same.

9.6   To  the  extent that any Intra-Group  Indebtedness  is
found  to be owing from any member of the Vendor's Group  to
any  of the Overseas Companies, the Purchaser undertakes  to
procure  that the relevant Overseas Company shall waive  the
same.

9.7   The Purchaser hereby irrevocably grants to the  Vendor
the  right  to  acquire, and the Vendor  hereby  irrevocably
grants  to  the  Purchaser the right to sell,  the  Overseas
Companies  for  a  consideration of  BP1  for  each  Overseas
Company, in each case exercisable with effect from  31  July
1998.   The  right  to  acquire or the  right  to  sell,  as
applicable,  shall be exercised by notice  in  writing  (the
Notice) delivered by the party exercising the right  to  the
other.

9.8   If  the  option  granted pursuant  to  Clause  9.7  is
exercised,  the  Vendor and the Purchaser  will  within  one
month  of  receipt  of  the Notice  enter  into  a  transfer
agreement  on substantially similar terms to those contained
in  the  Transfer Documents and, in addition, containing  an
indemnity  from  the  Purchaser to the Vendor  with  similar
scope  and extent to the indemnity in Clause 9.4 in  respect
of liabilities coming into existence after Completion.

Product Liability

10.1  The  Vendor  hereby covenants to  indemnify  and  hold
harmless  the Cox Group and the Purchaser from  and  against
any and all losses, liabilities or costs incurred by any  of
them  as  a direct result of any litigation or claim whether
arising before or after Completion against either Cox  Group
Company or the Purchaser, arising from the manufacture, sale
or  supply  by  either  Cox Group Company  on  or  prior  to
Completion of products which:

          (i)   are defective or harmful (including, without
          limitation,   as   a  result  of  having   carried
          inaccurate or misleading warnings); or
          
          (ii)   do  not  comply  with  any  warranties   or
          representations made in writing by the  Cox  Group
          Company  in  question or implied by  law  (Product
          Liability Claims).
          
10.2  The Vendor shall co-operate with the Cox Group Company
in (a) providing (and procuring that their insurance brokers
provide)   copies   of,  and  information  concerning,   all
insurance  policies and loss runs relating to the operations
of  either  Cox  Group Company (other than  in  relation  to
Product   Liability  Claims)  for  time  periods  prior   to
Completion  and  (b) filing all claims (other  than  Product
Liability  Claims)  which the Purchaser reasonably  believes
appropriate  under policies of insurance maintained  by  any
member  of the Vendor's Group with respect to the operations
of  either  Cox  Group Company at or before Completion.  The
Vendor  will  forward  copies  of  all  correspondence  with
respect  to  such claims to the Purchaser and  will  forward
materials to the insurer as requested by the Purchaser.  The
Vendor  will not take any action to compromise or  otherwise
affect any such claims without the consent of the Purchaser.
Any  amounts  received  by the Vendor  from  an  insurer  in
respect  of  any claims filed pursuant to this  Clause  10.2
shall  be  forwarded forthwith to the Purchaser or  the  Cox
Group Company, as applicable.

10.3  For the avoidance of doubt, none of the provisions  of
Clause 7 shall apply to any amount which would otherwise  be
recoverable  by  the Purchaser from an insurer  pursuant  to
Clause 10.2.


Entire agreement

11.   This Agreement, together with all other agreements  to
be  executed  in  accordance with its terms,  sets  out  the
entire  agreement and understanding between the  parties  in
respect of the sale and purchase of the Shares and the  sale
and purchase of the Overseas Shares pursuant to the Transfer
Agreements.   This Agreement supersedes any  confidentiality
undertaking which shall cease to have any further  force  or
effect.  It is agreed that:

(a)  neither  party  has  entered  into  this  Agreement  in
     reliance   upon   any   representation,   warranty   or
     undertaking  of the other party which is not  expressly
     set out or referred to in this Agreement;
     
(b)  a  party  may claim in contract for breach of  Warranty
     under  this  Agreement but, subject  to  clause  11(c),
     shall  have no claim or remedy under this Agreement  in
     respect  of  misrepresentation (whether   negligent  or
     otherwise, and whether made prior to, and/or  in,  this
     Agreement) or untrue statement made by the other party;
     
(c)  this  clause  shall  not  exclude  any  liability   for
     fraudulent misrepresentation.
     
     
Variation

12.  No variation of this Agreement (or any document entered
into pursuant to this Agreement) shall be valid unless it is
in writing and signed by or on behalf of each of the parties
hereto.

Assignment

13.   No  party  may assign or transfer all or  any  of  its
rights  or  obligations hereunder without the prior  written
consent of the other party except that the Vendor may assign
its  rights under this Agreement and the Transfer Agreements
to any other member of the Vendor's Group.

Announcements

14.   Except so far as may be required by any applicable law
or   by   any   of  the  regulatory  requirements   of   any
jurisdiction,  including  the  rules  of  the  London  Stock
Exchange  Limited,  or of The City Code  on  Take-Overs  and
Mergers, no announcement or circular in connection with  the
subject matter of this Agreement shall be made or issued  by
or  on  behalf  of  either party without the  prior  written
approval  of the other (such approval not to be unreasonably
withheld or delayed).

Costs

15.   Each  of  the parties hereto shall pay its  own  costs
incurred in connection with the negotiation, preparation and
implementation of this Agreement and the Purchaser shall pay
all  stamp duty and stamp duty reserve tax (if any)  on  the
transfer  of  the Shares together with all  stamp  duty  and
stamp  duty  reserve  tax (if any) on the  transfer  of  the
Overseas Shares and any notarial fee or analogous expenses.

Invalidity

16.   If  any term or provision of this Agreement  shall  be
held  to  be illegal or unenforceable, in whole or in  part,
under  any  enactment or rule of law, such term or provision
or  part shall to that extent be deemed not to form part  of
this  Agreement but the enforceability of the  remainder  of
this  Agreement  shall not be affected.  The  parties  shall
then use all reasonable endeavours to replace the illegal or
unenforceable provision by a valid provision the  effect  of
which is as close as possible to the intended effect of  the
invalid or unenforceable provision.

Counterparts and Further Assurance

17.1  This  Agreement may be entered into in any  number  of
counterparts   and  by  the  parties  to  it   on   separate
counterparts,  each of which, when executed  and  delivered,
shall  be  an  original,  but  all  the  counterparts  shall
together constitute one and the same instrument.

17.2 At any time after Completion, the Vendor shall, at  the
Purchaser's expense, execute all such documents and  do  all
such things as the Purchaser may reasonably require for  the
purpose  of  vesting  in the Purchaser the  full  legal  and
beneficial title to the Shares and giving the Purchaser  the
full benefit of this Agreement.

Notices

18.1 Any notice under this Agreement shall be in writing and
signed  by  or on behalf of the party giving it and  may  be
served  by  leaving  it or sending it by facsimile,  prepaid
recorded delivery or registered post to the address and  for
the  attention of the relevant party set out in clause  18.2
(or as otherwise notified from time to time hereunder).  Any
notice  so  served by facsimile or post shall be  deemed  to
have been received:

(a)  in  the case of facsimile, twelve (12) hours after  the
     time of despatch;
     
(b)  in  the  case of recorded delivery or registered  post,
     forty  eight  (48) hours from the date  of  posting  if
     posted  in  the  United Kingdom to an  address  in  the
     United  Kingdom or seven days if posted to or  from  an
     address outside the United Kingdom.
     
18.2  The  addresses  of  the parties  for  the  purpose  of
clause 18.1 are as follows:

     The Vendor:    Hoechst AG

     For the attention of:    Heinz Zulauf

     Facsimile:          00 49 69 305 16308

     With a copy to:

     For the attention of:    Jan de Kock

     Fascimile:          00 49 69 305 82733

     The Purchaser: Alpharma (U.K.) Limited

     For the attention of:    Ingrid Wiik

     Facsimile:          00 47 22 52 93 40

     With a copy to:

     For the attention:  Robert Wrobel

     Fascimile:          00 1 201 592 1481

Governing Law And Jurisdiction

19.1  This  Agreement is governed by, and shall be construed
in accordance with, the laws of England.

19.2 Each of the parties hereby irrevocably submits, for the
benefit  of the other, to the non-exclusive jurisdiction  of
the courts of England.

In  Witness Whereof this Agreement has been signed by and on
behalf of the parties the day and year first before written.

                              
                              
                         SCHEDULE 1
                              
               The Company And The Subsidiary
                              
                           PART I
                              
                   Details of the Company
                              
1.   Registered Number:     3382754
                            
2.   Registered Office:     Whiddon Valley, Barnstaple,
                            Devon EX32 8NS
                            
3.   Directors:             
                            
     (a) Name:              Heinz Leonhard Zulauf
                            
     (b) Address:           Kastanienstrasse 1
                            Glashutten, Hessen, Germany
                            
     (c) Nationality:       German
                            
     Directors:             
                            
     (a) Name:              Peter Loscher
                            
     (b) Address:           33 Redwood Mansions,
                            Marlowe Road, London W8
                            
     (c) Nationality:       Austrian
                            
4.   Secretary:             Heinz Leonhard Zulauf
                            
5.   Authorised Capital:    BP3,000,000  (divided   into
                            ordinary shares of BP1 each)
                            
6.   Issued Capital:        BP2,416,002
                            
7.   Registered             Hoechst AG
     Shareholders:          
     
8.   Accounting  Reference  31 December
     Date:                  
     
9.   Auditors:              Coopers & Lybrand
                            
10.  Tax Residence:         UK
                            
11.  Tax    District   and  West     Midlands     Large
     Reference:             Business Office
                            468/94680/59102
                            
12.  VAT      Registration  N/A
     Number:                
     
13.  Subsidiaries:          Arthur   H.  Cox   &   Co.,
                            Limited
                            
14.  Mortgages         and  None
     Charges:               
     


                           PART II
                              
                  Details of the Subsidiary
                              
Arthur H. Cox & Co., Limited

1.   Name:                  Arthur H. Cox & Co., Limited
                            
2.   Date               of  30 December 1903
     Incorporation:         
     
3.   Place              of  London
     Incorporation:         
     
4.   Class of Company:      Private Company Limited by
                            Shares
                            
5.   Registered Number:     79585
                            
6.   Registered Office      Whiddon            Valley,
                            Barnstaple,
                            Devon EX32 8NS
                            
7.   Directors:             
                            
     (a)  Name:             David John Green
                            
     (b)  Address:          Florestan Graynfylde Drive
                            Bideford, Devon EX39 4AP
                            
     (c)  Nationality:      British
                            
     Directors:             
                            
     (a)  Name:             Peter John Grinstead
                            
     (b)  Address:          Pipits, Lower Park Road
                            Braunton, Devon EX33 2LQ
                            
     (c)  Nationality:      British
                            
     Directors:             
                            
     (a)  Name:             Michael John Leatham
                            
     (b)  Address:          Broomhill
                            High Bickington
                            Umberleigh
                            Devon EX37 8BL
                            
     (c)  Nationality:      British
                            
     Directors:             
                            
     (a)  Name:             Dr Peter Robert Read
                            
     (b)  Address:          Marchfields
                            6 Ashley Hill Place
                            Cockpole Green
                            Wargrave
                            Berkshire RG10 8NL
                            
     (c)  Nationality:      British
                            
8.   Secretary:             Peter John Grinstead
                            
9.   Authorised Capital:    BP1,380,000  (divided  into
                            ordinary  shares   of   BP1
                            each)
                            
10.  Issued Capital:        BP1,370,397
                            
11.  Registered             Cox Investments Limited
     Shareholders:          1,370,397 ordinary shares
                            
12.  Accounting  Reference  31 December
     Date:                  
     
13.  Auditors:              Coopers & Lybrand
                            
14.  Tax Residence:         UK
                            
15.  Tax    District   and  West     Midlands    Large
     Reference:             Business Office
                            468/94680/59102
                            
16.  VAT      Registration  192 3845 42
     Number:                
     
17.  Mortgages         and  None
     Charges:               
     


                              
                              
                         SCHEDULE 2
                              
                           Part A
                         Warranties
                              
1.   Disclosure

Deliberately omitted.

2.   The Shares

(a)  The  Shares  comprise  the  whole  of  the  issued  and
     allotted  share capital of the Company and all  of  the
     Shares are fully paid.
     
(b)  There  are  no  security interests, options,  equities,
     claims  or  other third party rights over or  affecting
     the  Shares and there is no agreement to give or create
     any such interest.
     
(c)  There  are  no  options or rights of first  refusal  to
     acquire  or subscribe for any shares in the capital  of
     the Company.
     
(d)  The  Company  has not engaged in any other business  or
     activity  other  than holding the  Shares  and  has  no
     material  liabilities or obligations, other than  those
     incurred as a result of holding the Shares.
     
3.   The Vendor's Capacity

(a)  The Vendor is the sole beneficial owner of the Shares.
     
(b)  The  Vendor  has  obtained all corporate authorisations
     required to empower it to enter into this Agreement and
     to perform its obligations hereunder in accordance with
     their terms.
     
(c)  The  Vendor's obligations under and performance of this
     Agreement do not conflict with any other obligation  or
     agreement of the Vendor.
     
4.   Subsidiary Company

(a)  The  Company  is  the beneficial owner  free  from  all
     encumbrances,  equities and claims (including  security
     interests, options and other third party rights in  the
     issued or unissued share capital of the Subsidiary)  of
     the whole of the share capital of the Subsidiary listed
     in Schedule 1 Part II.
     
(b)  Other than holding shares in the Non-Trading Companies,
     for  so long as the Subsidiary has been a member of the
     Vendor's Group, it has not been engaged in any activity
     other   than  the  pharmaceutical  business  and  other
     related activities.
     
(c)  None  of  the  Non-Trading Companies has  incurred  any
     liabilities  or obligations actual or contingent  (such
     term  being defined for these purposes by reference  to
     SSAP 18) (save in relation to incorporation and setting
     up   costs  and  expenses)  nor  is  involved  in   any
     litigation of any kind.  So far as the Vendor is aware,
     each  of  the Non-Trading companies is a subsidiary  of
     the Subsidiary.
     
5.   Good standing

The Company (a) is duly organised and validly existing under
the  laws of the place of its incorporation and (b) has full
corporate power and authority to carry on its business as it
is  now  being conducted and to own the material  properties
and  assets  it  now owns.  The Vendor has provided  to  the
Purchaser   a  copy  of  the  Memorandum  and  Articles   of
Association of the Company as in effect immediately prior to
this Agreement.

6.   Accounts for the year ended on the Accounts Date

The  Accounts of the Subsidiary, which have been audited  by
Coopers & Lybrand, gave a true and fair view of the state of
affairs of the Subsidiary at the Accounts Date, and  of  the
results  of the Subsidiary for the financial year  ended  on
the  Accounts Date and, so far as the Vendor is aware,  have
been  prepared  in all material respects in accordance  with
United Kingdom generally accepted accounting principles on a
basis   consistent  with  the  preparation  of  the  audited
accounts in respect of the 1996 financial year.

7.   Accounting Records

The  accounting  records of the Company and  the  Subsidiary
relevant  to  the  preparation and audit of their  statutory
accounts are in all material respects up to date and, so far
as  the  Vendor  is aware, reflect, in accordance  with  the
usual  practice in the applicable jurisdictions, the  assets
and  liabilities and all material transactions entered  into
by it.

8.   Position since the Accounts Date

Since the Accounts Date,:

(a)  no  dividend or other distribution (within the  meaning
     of  section 209, 210 or 418 of the Taxes Act) has  been
     declared,  paid or made by a Cox Group Company  (Except
     for  any dividends provided for in the Accounts of  the
     relevant Cox Group Company);
     
(b)  each member of the Cox Group has conducted its business
     in  the usual way so as to maintain that business as  a
     going concern;
     
(c)  no share or loan capital has been allotted or issued or
     agreed to be allotted or issued by a Cox Group Company;
     
(d)  neither member of the Cox Group has other than  in  the
     ordinary course of business acquired or disposed of, or
     agreed  to  acquire or dispose of businesses or  assets
     with an aggregate value in excess of BP250,000;
     
(e)  no   contract,  liability  or  commitment  (whether  in
     respect  of capital expenditure or otherwise) has  been
     entered  into by either member of the Cox  Group  which
     will  continue  in  force for more than  twelve  months
     after Completion or which involved or could involve  an
     obligation  of  a  material  nature  or  magnitude   (a
     liability  for expenditure in excess of BP250,000  being
     material for this purpose);
     
(f)  no debtor owing in excess of BP100,000 has been released
     by  either Cox Group Company on terms that it pays less
     than  the book value of its debt and no debt in  excess
     of  BP100,000 owing to either Cox Group Company has been
     deferred, subordinated or written off or has proved  to
     any extent irrevocable;
     
(g)  each Cox Group Company has paid its trade creditors  in
     all material respects in the ordinary course;
     
(h)  except  as  set  forth  in the 1998  Subsidiary  budget
     attached as Schedule 9 to the Disclosure Letter  or  as
     otherwise  disclosed, neither member of the  Cox  Group
     has  purchased  or contracted to purchase  any  capital
     assets with an aggregate value in excess of BP250,000;
     
(i)  there  have been no transactions by any member  of  the
     Cox  Group  with  any  member  of  the  Vendor's  Group
     otherwise than in the ordinary course of business; and
     
(j)  so  far as the Vendor is aware, save for the facts  and
     matters set out in the Disclosure Letter and for  facts
     and  matters  likely  to affect  to  a  similar  extent
     generally all companies carrying on similar businesses,
     there  are  no  other  facts  or  matters  which  might
     reasonably  be  expected  to have  a  material  adverse
     effect  on  the business of the Cox Group, taken  as  a
     whole.
     
9.   The Company's assets

(a)  So far as the Vendor is aware, the Cox Group owns or is
     entitled  to  use and enjoy all the rights  and  assets
     necessary  to  carry on the business of the  Cox  Group
     substantially  as  carried on in the  financial  period
     ended  on  the  Accounts Date, except  for  any  assets
     disposed  of  in the ordinary course of business  since
     that  date.  No asset (other than the Properties) owned
     by  any  Cox  Group Company with a value in  excess  of
     BP50,000  is  the  subject of any security  interest  or
     option or similar encumbrance, except for:
     
     (i)  any hire or lease agreement in the ordinary course
          of business;
          
     (ii) title retention provisions in respect of goods and
          materials  supplied  to  the  Cox  Group  in   the
          ordinary course of business;
          
     (iii)      the security interests, if any, reflected in
          the  Accounts  and liens arising in  the  ordinary
          course of business by operation of law.
          
(b)  The  Properties are all the properties owned or  leased
     by the Cox Group.
     
(c)  The entire legal estate and beneficial interest in each
     of the Properties is vested in a Cox Group Company.
     
(d)  So far as the Vendor is aware, no Cox Group Company has
     entered  into a lease of any property which predates  1
     January 1996 which is not one of the Properties and  in
     respect  of  which a Cox Group Company has  received  a
     valid  notice  under section 17(1) of the Landlord  and
     Tenant (Covenants) Act 1995 which is subsisting.
     
(e)  Copies  of all leases material to the business  of  the
     Cox Group Company are contained in the Data Room.
     
(f)  So  far  as  the  Vendors  are  aware  the  transaction
     contemplated  by  this Agreement  will  not  materially
     alter  or  affect  any  of  the  terms  and  conditions
     (including,  without  limitation,  the  rents   payable
     thereunder) of any of the leases pursuant  to  which  a
     Cox  Group  Company  holds  the  Properties.   Save  as
     disclosed, the Subsidiary has not received notification
     of  any  subsisting  claim for  a  material  breach  of
     contract in respect of the leases pursuant to  which  a
     Cox  Group  Company  holds the Properties  nor  is  the
     Vendor  aware of any subsisting material breach of  the
     said leases by the lessor.
     
10.  Debts

Except for indebtedness or loans to third parties disclosed,
referred  to or provided for in the Accounts, the Cox  Group
does  not  have outstanding any  loans in excess of BP250,000
to  third  parties which have arisen otherwise than  in  the
normal course of the Subsidiary's business.

11.  Contractual matters

(a)  The  Subsidiary  has made available  to  the  Purchaser
     copies  of  the  contracts  and  agreements  which  are
     material  to the business of the Subsidiary which  have
     been entered into by the Subsidiary as specified in the
     Disclosure Letter and, so far as the Vendor  is  aware,
     no  third  party  is  in  default  under  any  of  such
     contracts  where  such default would  have  a  material
     adverse  effect on the Cox Group and,  so  far  as  the
     Vendor is aware, such agreements and contracts have not
     been terminated or varied in any material respect since
     such copies were so made available.
     
(b)  Save  as disclosed, the Company and the Subsidiary have
     not  received  written notification of  any  claim  for
     breach  of  contract in respect of  the  contracts  and
     agreements  referred  to above  and  no  litigation  or
     similar proceedings have been instituted nor, so far as
     the  Vendor  is  aware, is any third party  in  default
     under  any  of such contracts where such default  would
     have a material adverse effect on the Cox Group.
     
(c)  Save  as  disclosed,  there  is  not  outstanding   any
     guarantee,  indemnity  or  suretyship  by  either   the
     Company  or  the Subsidiary in respect of any  material
     obligation of any third party.
     
(d)  Except  as set out in the document attached as Schedule
     4  to  the  Disclosure Letter, the  Subsidiary  is  not
     prohibited by contract from selling its top 23 products
     (being  those products listed in the document  attached
     as Schedule 5 to the Disclosure Letter) anywhere in the
     world.
     
(e)  The  document attached as Schedule 6 to the  Disclosure
     Letter   contains  a  complete  list  of  all  material
     contracts between each Cox Group Company and any member
     of the Vendor's Group.
     
(f)  The  document attached as Schedule 7 to the  Disclosure
     Letter   contains  a  complete  list  of  all  material
     contracts  which, by virtue of the acquisition  of  the
     Shares by the Purchaser, will result in any other party
     becoming entitled to exercise any right of termination.
     
12.  Litigation and Regulatory matters

(a)  Save as disclosed, the Company or the Subsidiary is not
     engaged in, and, so far as the Vendor is aware, has not
     been  threatened  in writing with,  any  litigation  or
     arbitration or similar proceedings which, if  adversely
     determined,  individually or collectively are  regarded
     or  ought  reasonably to be regarded by the  Vendor  as
     likely  to  have  a  material  adverse  effect  on  the
     financial position of the Cox Group.
     
(b)  Save  as  disclosed, the Cox Group has, so far  as  the
     Vendor is aware, in all material respects conducted its
     business  and corporate affairs in accordance with  all
     applicable laws and regulations.
     
(c)  Save  as disclosed, so far as the Vendor is aware,  the
     Cox   Group   has   obtained  all  material   licences,
     permissions,  authorisations and consents required  for
     the  carrying on of its business in the places and  the
     manner in which such business is now carried on; and
     
(d)  Save  as  disclosed, so far as the Vendor is aware,  no
     state  or  official investigation or enquiry concerning
     the Cox Group is in progress.
     
(e)  The  document attached as Schedule 8 to the  Disclosure
     Letter  contains  a  substantially  complete  list,  by
     product   and   country,  of  those   foreign   product
     registrations for the top 23 products of the Subsidiary
     which, so far as the Vendor is aware, are registered as
     at  the  date of this Agreement, where the consequences
     of  such  product  registrations not  being  registered
     would be materially adverse to the Cox Group.
     
13.  Directors and Employees

(a)  The  Vendor has made available to the Purchaser a  list
     of  all  the  employees of the Cox Group  whose  annual
     salary excluding bonuses exceeds BP50,000 together  with
     details of their remuneration, copies of all applicable
     collective  bargaining agreements and  a  copy  of  the
     relevant   Cox  Group  Company's  standard  terms   and
     conditions  of  employment.  The Vendor has  also  made
     available details of the remuneration of the members of
     the  board  of  directors  of the  relevant  Cox  Group
     Company  where those directors are remunerated  by  the
     relevant Cox Group Company for holding that office.
     
(b)  Save  as disclosed, so far as the Vendor is aware,  the
     Cox Group, in relation to each of its employees and  so
     far  as  relevant to each of its former employees,  has
     complied  in  all material respects with  all  relevant
     statutes,  regulations,  codes of  conduct,  collective
     agreements,  orders  and  awards  relevant   to   their
     conditions  of service or to the relations  between  it
     and its employees or any recognised trade union.
     
14.  Insurance

(a)  The  Vendor has made available to the Purchaser details
     of the insurances maintained by or on behalf of the Cox
     Group.   The  Vendor  is  not  aware  of  any  material
     outstanding  claims  under or in  respect  of  (i)  the
     validity of any policies of insurance maintained by the
     Cox Group or (ii) whether any claim notified in writing
     is  covered  by  the policy of insurance against  which
     such claim has been made.
     
(b)  Completion  will not affect any rights  of  either  Cox
     Group   Company   under  the  policies   of   insurance
     maintained by them or on their behalf to continue or to
     make  a claim in relation to an event which occurs,  or
     has  occurred, prior to Completion, to the extent  that
     such  event would have given rise to an insurance claim
     under  such  policies of insurance had the  Shares  not
     been acquired by the Purchaser.
     
15.  Pensions

Definitions

In this paragraph:

Actuarial  Valuation means the actuarial  valuation  of  the
Pension  Scheme as at 1 October 1996 prepared by R.J.  Sweet
of I.S. Cartwright & Co.;

Employees   means   the  officers  and  employees   of   the
Subsidiary, and Employee means any one of them;

Pension  Scheme  means the Arthur H. Cox &  Company  Limited
Retirement Benefit Scheme;

Trustees means the trustees of the Pension Scheme.

(a)  Other than the state pension scheme, the Pension Scheme
     is  the  only  arrangement under which  the  Subsidiary
     provides or is liable to provide relevant benefits  (as
     defined  in section 612(1) of the Taxes Act) in respect
     of any past or present Employee.
     
(b)   The  Vendor  or  its advisers have  disclosed  to  the
Purchaser or its advisers:

          (i)   copies of the trust deed and rules governing
          the Pension Scheme;
          
          (ii)  copies  of  all  benefit  announcements  and
          correspondence (if any) under which members of the
          Pension  Scheme are granted special  benefits  not
          documented  in the trust deed and rules  governing
          the Pension Scheme;
          
          (iii)     a copy of the Actuarial Valuation; and
          
          (iv)  a  list  as at 13 March 1998 of the  current
          Employees who are members of the Pension Scheme.
          
(c)  The  Pension  Scheme  is  exempt  approved  within  the
     meaning of Chapter I of Part XIV of the Taxes Act  and,
     to  the Vendor's knowledge, there is no matter which it
     recognises could reasonably cause the Inland Revenue to
     withdraw  such approval.  There is in force in  respect
     of  the  Pension  Scheme a contracting-out  certificate
     (within the meaning of section 7 of the Pension Schemes
     Act  1993)  and,  so far as the Vendor  is  aware,  the
     Pension   Scheme  has  been  administered  in  material
     compliance  with the Pension Schemes Act 1993  and  the
     Pensions Act 1995.
     
(d)  As  far  as  the  Vendor is aware, no amounts  due  and
     payable   by   the  Subsidiary  to  the  Trustees   are
     outstanding and no such amounts have been requested.
     
(e)  As  far as the Vendor is aware, the Subsidiary and  the
     Trustees  have  complied in all material respects  with
     their  respective obligations under the Pension  Scheme
     (including under Article 119 of the Treaty of Rome  and
     the  Pensions Act 1995) in relation to past and present
     Employees   (other   than  its  obligations   for   sex
     equalisation in relation to GMPs).
     
(f)  Neither the Vendor nor, so far as the Vendor is  aware,
     the  Trustees  or the Subsidiary have received  written
     notice  of  any material claim being made or threatened
     by  any Employee against the Subsidiary or the Trustees
     in relation to the Pension Scheme.
     
(g)  All   lump  sum  benefits  (other  than  a  refund   of
     contributions) payable from the Pension Scheme on death
     in service, sickness and disability are insured with an
     insurance company.
     
(h)  The  Actuarial  Valuation disclosed that the  aggregate
     value  of the assets of the Pension Scheme at the  date
     of  the  valuation  were equal to or greater  than  the
     aggregate  value  of  the liabilities  assessed  on  an
     ongoing   basis  calculated  in  accordance  with   the
     actuarial methods and assumptions used in the Actuarial
     Valuation.   The  Vendor is not  aware  of  any  action
     having  been  taken (except in the ordinary  course  of
     business) by the Vendor, the Subsidiary or the Trustees
     since  the  date of the Actuarial Valuation that  would
     have   a  materially  adverse  effect  on  the  funding
     position  of  the  Pension Scheme as disclosed  in  the
     Actuarial Valuation.
     
(i)  The  Subsidiary has no obligation or liability  (actual
     or  contingent, present or future) to contribute to any
     personal pension scheme (as defined in section  630  of
     the Taxes Act) in respect of any of its Employees.
     
(j)  To  the  Vendor's knowledge no action  has  been  taken
     under  the  Pension Scheme to augment  benefits  beyond
     those  set  forth  in the written Scheme  or  admit  to
     membership a person not otherwise eligible.
     
(k)  To the Vendor's knowledge, the only part-time employees
     excluded  from the Pension Scheme are those who  worked
     16 or less hours per week.
     
16.  Intellectual Property

Definitions

In this paragraph:

Intellectual  Property  Rights means patents,  trade  marks,
service   marks,  trade  names,  design  rights,   copyright
(including  rights in computer software),  database  rights,
rights  in know-how and other intellectual property  rights,
in   each  case  whether  registered  or  unregistered   and
including applications for the grant of any such rights  and
all  rights  or  forms  of protection having  equivalent  or
similar effect anywhere in the world;

(a)  Details of all registered Intellectual Property  Rights
     (including applications for registration) are  set  out
     in  the Disclosure Letter.  The Subsidiary is the legal
     or  beneficial owner of such registered rights.  So far
     as the Vendor is aware, such rights are not the subject
     of  any mortgage, charge, lien, other security interest
     or  licence.   The  Vendor  has  not  received  written
     notification  from  any  third  party  challenging  the
     validity of any such Intellectual Property Rights.
     
(b)  So  far  as the Vendor is aware, none of the operations
     of  the  Cox  Group infringe any Intellectual  Property
     Rights of any third party.
     
(c)  The  document attached as Schedule 10 to the Disclosure
     Letter sets forth a substantially complete list of  all
     material  products under development.  So  far  as  the
     Vendor is aware, there are no facts or circumstances in
     existence which would result in such products, on their
     introduction,  infringing  the  Intellectual   Property
     Rights, in existence and as known to the Vendor  as  at
     the date of this Agreement.
     
                              
                              
                           Part B
                       Tax Warranties
                              
Definitions

1.   In this Part B of Schedule 2:

1.1   Tax and tax authority shall have the same meanings  as
they have for the purposes of the Tax Covenant.

1.2   References  to  any  provision  of  an  enactment  are
references  to it as from time to time amended, consolidated
or  re-enacted  (with  or  without modification),  and  also
include any provision replaced by such provision.

General/compliance

Accounts

2.1  All material liabilities, whether actual or deferred of
each  Cox  Group  Company for tax measured by  reference  to
income, profits or gains earned, accrued or received  on  or
before  the Accounts Date or arising in respect of an  event
occurring or deemed to occur on or before the Accounts  Date
are  fully provided for or (as appropriate) disclosed in the
Accounts.

Returns etc.

2.1   Each  Cox  Group  Company has  duly,  and  within  any
appropriate  time  limits,   made  all  returns,  given  all
notices  and supplied all other information required  to  be
supplied  to all relevant tax authorities and has maintained
all  records required to be maintained for tax purposes; all
such  information was and remains complete and  accurate  in
all  material respects and all such returns and notices were
and  remain  complete and accurate in all material  respects
and were made on the proper basis.

Disputes, investigations

2.2   Neither Cox Group Company is involved in any  material
current dispute with any tax authority or is or has  in  the
last  three  years  been the subject of  any  investigation,
audit or non-routine visit by any tax authority.

Penalties, interest

2.3   Within the past three years, no Cox Group Company  nor
any director or officer of any such company (in his capacity
as  such)  has  paid or become liable to  pay,  to  any  tax
authority,  any  penalty,  fine, surcharge  or  interest  in
respect of tax (including in respect of any failure to  make
any return, give any notice or supply any information to any
relevant tax authority, or any failure to pay tax on the due
date for payment).

Special arrangements

2.4   No tax authority has operated or agreed to operate any
special arrangement (being an arrangement which is not based
on  relevant  legislation  or  any  published  practice)  in
relation to the affairs of either Cox Group Company.

Withholdings

2.5   Each  Cox  Group  member has made all  deductions  and
retentions  of or on account of tax as it was or is  obliged
to  make  and all such payments of or on account of  tax  as
should  have  been made to any tax authority in  respect  of
such deductions or retentions.

Employees

3.    All  National Insurance contributions and sums payable
to  the  Inland  Revenue under the P.A.Y.E. system  due  and
payable  by  either Cox Group Company up to the date  hereof
have  been paid and each Cox Group Company has made all such
deductions  and  retentions as should have been  made  under
section  203  to  203L of the Taxes Act and all  regulations
made thereunder.

Company residence etc.

Residence

4.    Each  Cox Group Company is and has at all  times  been
resident in the United Kingdom for tax purposes and  is  not
and   has  not  been  treated  as  resident  in  any   other
jurisdiction  for  any  tax purpose  (including  any  double
taxation arrangement).

Value added tax

5.1  For the purposes of this paragraph 5 the expression VAT
legislation shall include the Value Added Tax Act  1994  and
all  other enactments in relation to value added tax and all
notices, provisions and conditions made or issued thereunder
including  the  terms  of any agreement  reached  with  H.M.
Commissioners  of  Customs  and  Excise  or  any  concession
referred to in the Disclosure Letter.

5.2  In relation to each Cox Group Company:

(a)  it  is registered for the purposes of value added  tax,
     has  been  so registered at all times that it has  been
     required to be registered by VAT legislation, and  such
     registration  is not subject to any conditions  imposed
     by or agreed with H.M. Customs and Excise;
     
(b)  it has complied fully with and observed in all material
     respects the terms of VAT legislation;
     
(c)  it  has  maintained and obtained at all times complete,
     correct  and  up-to-date records,  invoices  and  other
     documents (as the case may be) appropriate or requisite
     for  the  purposes of VAT legislation and has preserved
     such records, invoices and other documents in such form
     and   for   such  periods  as  are  required   by   VAT
     legislation;
     
(d)  it  is  not and has not been treated as a member  of  a
     group for the purposes of VAT legislation, and has  not
     applied for such treatment;  and
     
(e)  it   is  not  and  has  not  been  subject  under   VAT
     legislation  to  any penalty liability notice,  written
     warning  of  failure  to  comply,  surcharge  liability
     notice  or  requirement to give security as a condition
     of making taxable supplies.
     
Stamp duty

6.   All documents in the possession or under the control of
a  Cox  Group  Company or to the production of which  a  Cox
Group  Company is entitled which establish or are  necessary
to  establish  the  title  of a Cox  Group  Company  to  any
material asset have been duly stamped.

Capital Gains

7.    No  asset has been acquired by a Cox Group Company  in
the  period of six years ending on the date of Agreement  in
circumstances   where  Section  171  of  the   Taxation   of
Chargeable  Gains Act 1992 applied to the  transfer  and  no
charge  under section 179 of that Act will arise as a result
of the entry into or performance of this Agreement.

Transfer Pricing

8.    Neither Cox Group Company since the Accounts Date  has
been  party to a transaction in respect of which a direction
has  been made or, so far as the Vendor is aware, is  likely
to be made, by the Board of the Inland Revenue under section
770(2)(d) of the Taxes Act.

                              
                              
                         SCHEDULE 3
                              
                         Properties
                              
Freehold                      
                              
Land lying to the south of   Title number:  DN371194
Castle Park Road, Whiddon     Proprietor:Arthur H. Cox &
Valley, Barnstaple                       Co Limited
                                         
Land lying to the south of   Title number:  DN325946
Westacott Road, Landkey       Proprietor:Arthur H. Cox &
                                         Co Limited
                                         
Land at Whiddon Valley,      Title number:  DN279393
Barnstaple                    Proprietor:Arthur H. Cox &
                                         Co Limited
                                         
Leasehold                    

Land buildings and premises  Landlord:  Devon County
situate at Whiddon Valley,   Council
Barnstaple                   Tenant:    Arthur H. Cox &
                                         Co Limited
                             Term:      99 years from
                                         1 July 1979
                             Rent:      BP1 p.a
                                         
Land at Westacott Road,      Landlord:  Devon County
Whiddon Valley, Barnstaple   Council
                             Tenant:    Arthur H. Cox &
                                         Co Limited
                             Term:      1 July 1984 to 30
                                         June 2078
                             Rent:      BP1 p.a
                             
Premises at Whiddon Drive,   Landlord:  B Ford  M A Ford
Barnstaple                               R Ford  M R A
                                         Ford
                             Tenant:    Arthur H. Cox &
                                         Co Limited
                             Term:      15 years
                                         commencing on 25
                                         March 1997
                             Rent:      BP80,000 p.a.
                             


                              
                              
                         SCHEDULE 4
                              
  Specific Accounting Policies and Procedures to be used in
              preparing the Net Asset Statement
                              
Subject to the points listed below in this Schedule  4,  the
Net  Asset  Statement will be prepared on the basis  of  the
accounting policies and procedures employed in producing the
Accounts:

(i)  Tangible fixed assets will continue to be accounted for
     on the basis of cost less accumulated depreciation;
     
(ii) no revaluation of Tangible fixed assets will take place
     in the preparation of the Net Asset Statement; and
     
(iii)       the  expected  useful  economic  lives  and  the
     estimated residual values of the Tangible fixed  assets
     owned  or  leased by the Subsidiary as at the  Accounts
     Date  will  not be revised or changed as  part  of  the
     preparation of the Net Asset Statement;
     
(iv) reserves  for  all appropriate items, including  Stocks
     and  Debtors shall be made on the same basis as in  the
     Accounts;
     
(v)  all  other  adjustments or closing entries  which  were
     made  in connection with the preparation of the Balance
     Sheet  contained  in the Accounts will  be  made  in  a
     consistent manner in the preparation of the  Net  Asset
     Statement; and
     
(vi) no credit shall be given for any increase in Net Assets
     due  to profit on sales to any Overseas Company to  the
     extent that such sales increased the inventory of goods
     sold to the relevant Overseas Company by the Subsidiary
     (the  Inventory Level) of the relevant Overseas Company
     to  a level in excess of the equivalent Inventory Level
     at 31 December 1997.
     
                              
                              
                         SCHEDULE 5
                              
                        Tax Covenant
                              
Interpretation

1.1   In this Schedule the following definitions shall  have
the following meanings:

Business Day means a day (other than a Saturday) when  banks
are  open for the transaction of normal banking business  in
London;

Purchaser's  relief  means a relief to the  extent  that  it
either  arises  in respect of an event occurring  or  period
commencing  after Completion, or was taken into  account  in
computing the provision for deferred tax in the Accounts  or
in  eliminating  such  provision, or  was  included  in  the
Accounts as an asset;

relief includes, unless the context otherwise requires,  any
allowance,  credit,  deduction,  exemption  or  set-off   in
respect  of  any tax or relevant to the computation  of  any
income, profits or gains for the purposes of any tax, or any
right to repayment of or saving of tax, and any reference to
the use or set off of relief shall be construed accordingly;

Retained  Group  means the Vendor and any other  company  or
companies (other than the Company and the Subsidiary)  which
either are or become, or have within the six years ending at
Completion  been, subsidiaries of the Vendor or  treated  as
members of the same group as the Vendor for any tax purpose;

tax  means corporation tax, advance corporation tax,  income
tax,  capital gains tax, inheritance tax, value  added  tax,
national  insurance contributions, capital duty, stamp  duty
reserve tax, duties of customs and excise, all taxes, duties
or  charges  replaced by or replacing any of them,  and  all
other  taxes  on  gross  or net income,  profits  or  gains,
distributions, receipts, sales, franchise, value added,  and
all  levies, imposts, duties, charges or withholdings in the
nature of taxation, together with all penalties, charges and
interest relating to any of the foregoing or to any late  or
incorrect return in respect of any of them (save insofar  as
attributable to the delay or default after Completion of the
Company,  the  Subsidiary or the Purchaser  (otherwise  than
through the agency of the Vendor pursuant to paragraph 8  or
11));

tax  authority means any taxing or other authority  (whether
of  the United Kingdom or elsewhere) competent to impose any
tax liability;

tax claim means the issue of any notice, demand, assessment,
letter  or  other  document by  or  on  behalf  of  any  tax
authority or the taking of any other action by or on  behalf
of  any  tax  authority  (including the  imposition  of  any
withholding), from which notice, demand, assessment, letter,
document  or action it appears that a tax liability  may  be
imposed on the Company or the Subsidiary;

tax liability means:

(a)  a liability of the Company or the Subsidiary to make or
     suffer an actual payment of tax; and
     
(b)  the  use  or  set  off  of  any Purchaser's  relief  in
     circumstances where, but for such use or set  off,  the
     Company  or  the Subsidiary would have  had  an  actual
     liability  to  tax  in respect of which  the  Purchaser
     would have been able to make a claim against the Vendor
     under  this  Schedule (the amount of the tax  liability
     for  these  purposes being deemed to be  equal  to  the
     amount of the actual liability to tax that is saved  by
     the use or set off of the Purchaser's relief); provided
     that  the  Purchaser shall procure that  reliefs  other
     than  any  Purchaser's  relief  are  used,  so  far  as
     reasonably  practicable,  to  offset  any  such  actual
     liability  to  tax,  and  if it  cannot  be  determined
     whether  a Purchaser's relief or another relief  is  so
     used,  it shall be assumed that another relief is  used
     in priority to any Purchaser's relief;
     
1.2   Persons shall be treated as connected for the purposes
of this Schedule if they are connected within the meaning of
section 839 of the Taxes Act.

1.3   The  headings in this Schedule shall  not  affect  its
interpretation.

Covenant to pay

2.    The Vendor hereby covenants with the Purchaser to  pay
to  the Purchaser, by way of adjustment to the consideration
for  the sale of the Shares, an amount equivalent to any tax
liability  arising  in respect of, by  reference  to  or  in
consequence of:

(a)  any  income,  profits  or  gains  earned,  accrued   or
     received on or before Completion;
     
(b)  any event which occurred on or before Completion (other
     than  any  tax liability arising in respect of  profits
     earned after Completion as a result of such event);
     
(c)  any  liability  of the Company or the Subsidiary  under
     section 767A, 767B or 767AA of the Taxes Act in respect
     of a tax liability of a member of the Retained Group.
     
Exclusions

3.    The covenant contained in paragraph 2 shall not  cover
any tax liability to the extent that:

(a)  provision  or reserve in respect of that tax  liability
     has been made in the Accounts, or the tax liability has
     been  noted  in  or  was  taken  into  account  in  the
     preparation of the Accounts; or
     
(b)  the   tax  liability  was  paid  or  discharged  before
     Completion; or
     
(c)  the  tax liability arises in respect of or by reference
     to  any  income,  profits or gains earned,  accrued  or
     received  in  respect  of  the  period,  or  any  event
     occurring, between the Accounts Date and Completion and
     which arises in the ordinary course of business of  the
     Company  or  the  Subsidiary  provided  that  for  this
     purpose the following shall be deemed not to be in  the
     ordinary course of business if they otherwise would be:
     
          (i)   any disposal (or deemed disposal for any tax
          purpose) of assets other than trading stock by the
          Company or the Subsidiary;
          
          (ii)  any  change in the use of an  asset  of  the
          Company or the Subsidiary;
          
          (iii)       anything  which  has  the  result   of
          requiring  disposal  value  to  be  brought   into
          account, or which crystallises a balancing charge,
          for   capital  allowances  purposes  (or  has  any
          similar  effect  under the laws  of  any  relevant
          foreign jurisdiction);
          
          (iv)  anything relating to or involving the making
          of   a  distribution  for  tax  purposes  or   the
          cancellation  or reorganisation of share  or  loan
          capital;
          
          (v)   the  Company or Subsidiary ceasing or  being
          treated  as ceasing to be a member of a  group  of
          companies;
          
          (vi)   anything  relating  to  a  transaction   or
          arrangement   or   series   of   transactions   or
          arrangements  undertaken  which  includes  a  step
          having  no  commercial or business  purpose  apart
          from the reduction, avoidance or deferral of a tax
          liability; or
          
          (vii)      any  transaction which is  not  entered
          into on arm's length terms.
          
(d)  the  tax liability arises as a result of any change  in
     rates of tax made after Completion or of any change  in
     law  or  the  published practice of any tax  authority,
     occurring after Completion; or
     
(e)  the  tax  liability would not have  arisen  but  for  a
     transaction, action or omission carried out or effected
     by any of the Purchaser, the Company or the Subsidiary,
     or  any other person connected with any of them, at any
     time after Completion, except that this exclusion shall
     not  apply  where  any  such  transaction,  action   or
     omission:
     
          (i)  is carried out or effected by the Company  or
          the  Subsidiary  pursuant  to  a  legally  binding
          commitment  created on or before Completion  or  a
          request of the Vendor pursuant to paragraph  8  or
          11; or
          
          (ii) is carried out or effected by the Company  or
          the  Subsidiary in the ordinary course of business
          of  the Company or the Subsidiary as carried on at
          Completion,  provided that for  this  purpose  the
          following  shall  be  deemed  not  to  be  in  the
          ordinary  course  of business  if  they  otherwise
          would  be  (with  the  effect that  the  exclusion
          contained in this paragraph 3(e) shall apply):
          
          (A)      any disposal (or deemed disposal for  any
             tax purpose) of assets other than trading stock
             by the Company or the Subsidiary;
             
          (B)      any change in the use of an asset of  the
             Company or the Subsidiary;
             
          (C)     anything which has the result of requiring
             disposal  value to be brought into account,  or
             which  crystallises  a  balancing  charge,  for
             capital allowances purposes (or has any similar
             effect  under the laws of any relevant  foreign
             jurisdiction);
             
          (D)      anything  relating to  or  involving  the
             making  of  a distribution for tax purposes  or
             the cancellation or reorganisation of share  or
             loan capital;
             
          (E)     the Company or Subsidiary ceasing or being
             treated as ceasing to be a member of a group of
             companies;
             
          (F)      anything  relating to  a  transaction  or
             arrangement   or  series  of  transactions   or
             arrangements undertaken after Completion  which
             includes   a  step  having  no  commercial   or
             business  purpose  apart  from  the  reduction,
             avoidance or deferral of a tax liability; or
             
(f)  the  tax liability arises as a result of a change after
     Completion in any accounting policy, or the  length  of
     any  accounting period for tax purposes, of the Company
     or the Subsidiary; or
     
(g)  such tax liability arises as a result of the Company or
     the Subsidiary failing (otherwise than by reason of any
     default  of  the  Vendor)  to submit  the  returns  and
     computations  required  to  be  made  by  them  or  not
     submitting  such  returns and computations  within  the
     appropriate time limits or submitting such returns  and
     computations otherwise than on a proper basis, in  each
     case after Completion; or
     
(h)  the tax liability arises as a result of the failure  of
     the  Purchaser to comply with its obligations contained
     in paragraph 8 or 11 hereof; or
     
(i)  any relief other than a Purchaser's relief is available
     to  the  Company  or the Subsidiary to set  against  or
     otherwise mitigate the tax liability (including but not
     limited   to   any  relief  available  under   any   of
     sections 393, 393A, 402 to 413, or section 240  of  the
     Taxes Act or section 102 of the Finance Act 1989)  (and
     so  that  (a)  for this purpose any relief  arising  in
     respect  of an accounting period falling partly  before
     and  partly after Completion shall be apportioned on  a
     time  basis, unless some other basis is more reasonable
     and (b) any relief that is so available in relation  to
     more  than  one  tax liability to which  this  Schedule
     applies shall be deemed, so far as possible, to be used
     in  such  a  way  as  to reduce to the  maximum  extent
     possible the Vendor's total liability hereunder); or
     
(j)  the tax liability would not have arisen but for:
     
          (i)  the making of a claim, election, surrender or
          disclaimer, the giving of a notice or consent,  or
          the  doing of any other thing under the provisions
          of any enactment or regulation relating to tax, in
          each  case  after Completion and by the Purchaser,
          the   Company,  the  Subsidiary  or   any   person
          connected with any of them and otherwise  than  at
          the request of the Vendor; or
          
          (ii)  the failure or omission on the part  of  the
          Company  or the Subsidiary to make any such  valid
          claim,  election, surrender or disclaimer,  or  to
          give any such notice or consent or to do any other
          such  thing, either as the Vendor may  require  in
          respect of periods or matters for which the Vendor
          has  conduct under paragraph 11 or, in respect  of
          periods  or matters for which the Vendor does  not
          have  conduct, in circumstances where the  making,
          giving or doing of which was taken into account in
          the  preparation  of  the Accounts  and  has  been
          notified  to  the  Purchaser in writing  within  3
          months of Completion; or
          
(k)  the  tax  liability arises in respect of  a  prepayment
     received in the ordinary course of business; or
     
(l)  the  tax  liability would not have arisen but  for  the
     winding  up  of,  or  the cessation  of  any  trade  or
     business  by,  the  Company  or  the  Subsidiary  after
     Completion, or any change in the nature or  conduct  of
     such trade or business after Completion; or
     
(m)  the  tax liability arises under Regulations 107 or  108
     or  Part XV of the Value Added Tax Regulations 1995  by
     reason   of   any  event  or  change  in  circumstances
     occurring after Completion.
     
3.2   The  Vendor shall have no liability to  the  Purchaser
under  any  part  of  this  Agreement  in  respect  of   any
non-availability, inability to use, or loss  or  restriction
of  any  relief  (failure of relief) where such  failure  of
relief  does  not  give  rise to a tax  liability  to  which
paragraph 2 applies.

Costs and expenses

4.   The covenant contained in this Schedule shall extend to
all  reasonable costs and expenses properly incurred by  the
Purchaser  in connection with a successful claim made  under
this  Schedule,  or  in  satisfying  or  settling  any   tax
liability in accordance with paragraph 8.

Double recovery

5.    The  Purchaser shall not be entitled  to  recover  any
amount pursuant to this Schedule in respect of any claim  to
the extent that the Purchaser, the Company or the Subsidiary
has  already recovered any amount in respect of  such  claim
under the Warranties or pursuant to any other agreement with
the  Vendor or any company connected with the Vendor, or  to
the  extent  that recovery has already been made under  this
Schedule in respect of the same subject matter.

Tax Refunds

6.1   The Purchaser shall promptly notify the Vendor of  any
right  to repayment or actual repayment of tax to which  the
Company or the Subsidiary is or becomes entitled or receives
in  respect of an event occurring or period (or part period)
falling   prior  to  Completion  (including  any   repayment
attributable  to  the surrender of group relief  or  advance
corporation tax in respect of a period ending on  or  before
Completion whenever such surrender is effected), where or to
the extent that such right or repayment was not included  in
the  Accounts as an asset and is not a payment or relief  to
which paragraph 10 below applies (a tax refund).

6.2   Any  tax refund actually obtained (less any reasonable
costs  of  obtaining  it  but  including  any  interest   or
repayment supplement) shall be dealt with as follows:

(a)  the  amount of the tax refund shall be set against  any
     payment  then due from the Vendor under this Agreement;
     and
     
(b)  to  the extent that there is an excess, a payment shall
     be  made  to the Vendor equal to the aggregate  of  any
     previous  payment or payments previously  made  by  the
     Vendor   under  this  Agreement  (and  not   previously
     refunded under this Agreement) up to the amount of  the
     excess  (any remaining excess being carried forward  to
     offset any further payment that may become due from the
     Vendor under this Agreement).
     
Section 767A Taxes Act 1988 etc.

7.1   The Purchaser hereby covenants with the Vendor to  pay
to the Vendor, by way of adjustment to the consideration for
the sale of the Shares, an amount equivalent to:

(a)  any  tax  for  which  the Vendor or  any  other  person
     falling within section 767A(2) of the Taxes Act becomes
     liable  by virtue of the operation of section 767A  and
     767B  of  the  Taxes  Act  in circumstances  where  the
     taxpayer company (as referred to in section 767A(1)) is
     the Company or the Subsidiary;
     
(b)  any  tax  for  which  the Vendor or  any  other  person
     falling  within  section  767AA(4)  of  the  Taxes  Act
     becomes   liable   by  virtue  of  the   operation   of
     section  767AA of the Taxes Act in circumstances  where
     the   transferred   company   (as   referred   to    in
     section  767AA(1)(a)) is the Company or the  Subsidiary
     (and for these purposes references to section 767AA are
     references  to the draft of that section  published  on
     17 February 1998, as (if relevant) subsequently amended
     and  as  subsequently  enacted, and  in  the  event  of
     amendments prior to enactment this paragraph  shall  be
     construed with any necessary modifications required  to
     give it effect); and
     
(c)  any  other  tax  for  which the Vendor  or  any  person
     connected  with it becomes liable as a  result  of  the
     failure  by the Company or the Subsidiary to  discharge
     it  (other than a tax liability covered by the covenant
     in paragraph 2).
     
7.2  The covenant contained in paragraph 7.1 shall:

(a)  extend to any costs reasonably and properly incurred by
     the Vendor or such other person in connection with such
     tax or a claim under paragraph 7.1;
     
(b)  not apply to tax to the extent that the Purchaser could
     claim  payment  in  respect of it  under  paragraph  2,
     except  to the extent a payment has been made  pursuant
     to  paragraph 2 and the tax to which it relates was not
     paid by the Company or the Subsidiary; and
     
(c)  not  apply  to  tax  which  has  been  recovered  under
     section  767B(2) of the Taxes Act or any other relevant
     statutory provision (and the Vendor shall procure  that
     no  such  recovery is sought to the extent that payment
     is made hereunder).
     
7.3   Paragraphs 8.1, 8.2 and 9 (conduct of disputes and due
date  for payment) shall apply to the covenant contained  in
paragraph  7.1 as they apply to the covenants  contained  in
paragraph  2,  replacing references to  the  Vendor  by  the
Purchaser  (and  vice versa) and making any other  necessary
modifications.

Notification of claims and conduct of disputes

8.1   If the Purchaser, the Company or the Subsidiary become
aware  of any tax claim which could give rise to a liability
for  the  Vendor under this Schedule (whether  alone  or  in
combination  with  other claims), the Purchaser  shall  give
notice to the Vendor of that tax claim (including reasonably
sufficient details of such tax claim, the due date  for  any
payment  and the time limits for any appeal, and so  far  as
practicable  the amount of the claim under this Schedule  in
respect  thereof) as soon as possible (and in any event  not
more  than 15 days after the Purchaser, the Company  or  the
Subsidiary becomes aware of such claim) and shall  take  (or
procure that the Company or the Subsidiary shall take)  such
action  as  the  Vendor  may reasonably  request  to  avoid,
dispute, resist, appeal, compromise or defend the tax  claim
and  any adjudication in respect thereof.  The Vendor  shall
have  the  right  (if it wishes) to control any  proceedings
taken in connection with such action, and shall in any event
be   kept   fully  informed  of  any  actual   or   proposed
developments (including any meetings) and shall be  provided
with copies of all correspondence and documentation relating
to  such  tax  claim or action, and such other  information,
assistance  and  access  to  records  and  personnel  as  it
reasonably requires.

8.2   The  Vendor  shall  reimburse  to  the  Purchaser  its
reasonable   costs   and  expenses  properly   incurred   in
connection  with  any  such action  or  proceedings  as  are
referred to in paragraph 8.1.

8.3   Subject to paragraph 8.4, the Purchaser shall  procure
that  no tax claim, action or issue in respect of which  the
Vendor  could  be  required to make  a  payment  under  this
Schedule  is  settled or otherwise compromised  without  the
Vendor's  prior  written consent, such  consent  not  to  be
unreasonably  withheld, and the Purchaser shall,  and  shall
procure that the Company and the Subsidiary and any of their
respective advisers shall, not submit any correspondence  or
return  or  send any other document to any tax authority  in
respect  of  pre-Completion  tax  affairs  (as  defined   in
paragraph  11.1) where the Purchaser or any such  person  is
aware  or could reasonably be expected to be aware that  the
effect  of  submitting  such  correspondence  or  return  or
sending  such  document would or could be to  put  such  tax
authority on notice of any matter which could give rise  to,
or  could  increase,  a claim under this  Schedule,  without
first  affording  the  Vendor a  reasonable  opportunity  to
comment  thereon and without taking account of such comments
so far as it is reasonable to do so.

8.4   If  the Vendor does not request the Purchaser to  take
any  appropriate  action within 30 days  of  notice  to  the
Vendor, the Purchaser shall be free to satisfy or settle the
relevant  tax  liability on such terms as it may  reasonably
think fit.

8.5   The  preceding  provisions of this paragraph  8  shall
apply,  as they apply to a tax claim, to any document issued
by  a  tax  authority from which it appears that any  amount
surrendered, or which is in the future surrendered,  by  way
of  group  relief (pursuant to Chapter IV of Part X  of  the
Taxes Act) by the Company or any Subsidiary to any member of
the Retained Group is or may be reduced or eliminated either
by  being  determined in a smaller amount, or by  being  the
subject  of  a  direction reducing such amount (pursuant  to
section 41A or 41B of the Taxes Management Act 1970), and so
that:

(a)  references to claims under, amounts due, or payments to
     be  made  under  this  Schedule shall  be  replaced  by
     appropriate    references   to   such   reduction    or
     elimination;
     
(b)  the   reference  to  the  relevant  tax  liability   in
     paragraph 8.4 shall be replaced by a reference to  such
     determination or reduction being accepted  without  any
     appeal being pursued; and
     
(c)  the  rights  of  the Vendor under paragraph  8.1  shall
     extend  to requiring the relevant surrendering  company
     to  make an adjustment as referred to in section  96(3)
     of  the  Finance Act 1990 on such terms as  the  Vendor
     thinks fit.
     
Due date of payment and interest

9.1   Subject to paragraph 9.2 the Vendor shall pay  to  the
Purchaser  any  amount payable under  this  Schedule  on  or
before  the date which is the later of the date ten Business
Days after demand is made therefor by the Purchaser and  two
Business  Days  before the first date on which  the  tax  in
question  becomes recoverable by the tax authority demanding
the  same.  Provided that, if the date on which the tax  can
be  recovered  is  deferred  following  application  to  the
relevant  tax authority, the date for payment by the  Vendor
shall  be two Business Days before such later date when  the
amount  of tax is finally and conclusively determined.   For
this purpose, an amount of tax shall be deemed to be finally
determined  when,  in respect of such amount,  an  agreement
under  section 54 of the Taxes Management Act  1970  or  any
legislative provision corresponding to that section is  made
or  a  decision of a court or tribunal is given  from  which
either  no  appeal lies or in respect of which no appeal  is
made within the prescribed time limit.  The Vendor may, with
the Purchaser's consent, not to be unreasonably withheld  or
delayed,  make  a  direct payment  in  respect  of  the  tax
liability   in  question  to  the  relevant  tax   authority
(including through use of certificates of tax deposit or the
equivalent)  and  the Vendor's liability  to  the  Purchaser
shall be treated as reduced or eliminated accordingly.

9.2  Where a claim under this Schedule relates to the use or
set off of a Purchaser's relief, the Vendor shall pay to the
Purchaser  the  amount due under this  Schedule  in  respect
thereof on the later of the date which is two Business  Days
before the first date on which tax which would not have been
payable  but for such use or set off becomes recoverable  by
the  tax authority demanding the same, and ten Business Days
after  demand is made therefor by the Purchaser, such demand
to  be  accompanied  by  a copy of a  certificate  from  the
auditors  of the Purchaser or the Company or the  Subsidiary
(obtained  or procured to be obtained by and at the  expense
of  the  Purchaser) that the Vendor has  a  liability  of  a
stated amount in respect of such claim and that tax has,  or
will  on a specified date, become payable as aforesaid,  and
by reasonably sufficient evidence of such use or set off and
of such tax liability.

9.3   Any  sum  not paid by the Vendor on the due  date  for
payment  specified  in  paragraph  9.1  or  9.2  shall  bear
interest (which shall accrue from day to day after  as  well
as  before any judgement for the same) at a rate  of  2  per
cent.  per  annum over the base rate of National Westminster
Bank  plc  from  the due date to and including  the  day  of
actual  payment  of  such sum, provided that  such  interest
shall  not  accrue to the extent that the Vendor's liability
under  paragraph  2 or paragraph 4 extends  to  interest  or
penalties  arising  after the due date.   Any  interest  due
under  this  paragraph shall be paid on the  demand  of  the
Purchaser on or following the date of payment of such sum.

Recovery from third parties

10.1  If  any  payment  is made by  the  Vendor  under  this
Schedule  in  respect of a tax liability and the  Purchaser,
the  Company or Subsidiary (or any person connected with any
of  them) either receives, or is entitled or may be entitled
either  immediately  or at some future date  to  recover  or
obtain,  from  any  person (other than  the  Purchaser,  the
Company  or  Subsidiary  or  any such  connected  person)  a
payment  or  relief  in  respect of  the  tax  liability  in
question, then:

(a)  the  Purchaser shall notify the Vendor of that fact  as
     soon as possible and if so required by the Vendor shall
     take  (or  shall procure that the Company or Subsidiary
     or  other  person concerned shall take) such action  as
     the  Vendor  may  reasonably request  to  enforce  such
     recovery  or to obtain such payment or relief  (keeping
     the Vendor fully informed of the progress of any action
     taken  and  providing it with copies  of  all  relevant
     correspondence and documentation); and
     
(b)  if  the  Purchaser,  the Company or the  Subsidiary  or
     other person concerned receives or obtains a payment or
     relief in respect of the tax liability in question, the
     Purchaser  shall pay to the Vendor the amount  received
     or  the  amount that the Purchaser, the Company or  the
     Subsidiary  or  other  person concerned  will  save  by
     virtue   of  the  payment  or  the  relief  (less   any
     reasonable  costs  of  recovering  or  obtaining   such
     payment   or  relief  and  any  tax  actually  suffered
     thereon) (the Benefit) to the extent that the amount of
     the  Benefit  does  not exceed the  aggregate  payments
     previously  made  by  the  Vendor  in  respect  of  all
     Relevant  Claims, and except where any amount so  saved
     would  otherwise have given rise to a claim under  this
     Schedule (in which event no such claim shall be  made).
     Any  amount  of the Benefit not so paid to  the  Vendor
     shall be carried forward and set off against any future
     Claims under this Schedule.
     
10.2  Any  payment  required to be  made  by  the  Purchaser
pursuant to paragraph 10.1 shall be made:

(a)  in  a  case  where the Purchaser, the  Company  or  the
     Subsidiary   or  other  person  concerned  receives   a
     payment,  within  five Business  Days  of  the  receipt
     thereof; and
     
(b)  in  a  case  where the Purchaser, the  Company  or  the
     Subsidiary or other person concerned obtains a  relief,
     on  or  before the date on which tax would have  become
     recoverable  by the appropriate tax authority  but  for
     the use of such relief.
     
10.3 The Purchaser shall procure that any such relief as  is
referred to in paragraph 10.2(b) is used in priority to  any
other relief, and in the absence of evidence to the contrary
it  shall  be  deemed to be so used.  The  Vendor  shall  be
entitled  to  require that the Company's and/or Subsidiary's
or other person's auditors shall certify the amount and date
of use of such relief for the purposes of this paragraph 10.

10.4  Any sum not paid by the Purchaser on the due  date  of
payment  specified  in paragraph 10.2  shall  bear  interest
(which  shall accrue from day to day after as well as before
any judgement for the same) at a rate per annum equal to the
rate of 2 per cent. per annum over the base rate of National
Westminster Bank plc from the due date to and including  the
day  of actual payment of such sum.  Such interest shall  be
paid on the demand of the Vendor.

Tax conduct

Interpretation

11.1 In this paragraph 11 and in paragraph 12:

accounting period means any period by reference to which any
income, profits or gains, or any other amounts relevant  for
the purposes of tax, are measured or determined;

pre-Completion  tax  affairs means the tax  affairs  of  the
Company   and  the  Subsidiary  for  which  the  Vendor   is
responsible under this paragraph 11;

tax  documents  means  the  tax returns,  claims  and  other
documents which the Vendor is required to prepare on  behalf
of  the  Company and the Subsidiary under paragraph  11.2(a)
and (b);

tax  return means any return required to be made to any  tax
authority  of  income,  profits or gains  or  of  any  other
amounts  or  information relevant for the purposes  of  tax,
including    any   related   accounts,   computations    and
attachments; and

time limit means the latest date on which a tax document can
be  executed or delivered to a relevant tax authority either
without  incurring interest or a penalty,  or  in  order  to
ensure that such tax document is effective.

Rights and Obligations of the Vendor

11.2  Subject  to and in accordance with the  provisions  of
this  paragraph  the  Vendor or its duly  authorised  agents
shall,  in  respect of all accounting periods ending  on  or
before Completion, and at its own cost:

(a)  prepare  and submit the tax returns of the Company  and
     the Subsidiary;
     
(b)  prepare on behalf of the Company and the Subsidiary all
     claims, elections, surrenders, disclaimers, notices and
     consents for the purposes of tax; and
     
(c)  (subject to paragraph 8) deal with all matters relating
     to  tax  which  concern or affect the  Company  or  the
     Subsidiary,  including the conduct of all  negotiations
     and  correspondence and the reaching of all  agreements
     relating thereto or to any tax documents.
     
11.3 Except with the Purchaser's written consent, the Vendor
shall not, and shall procure that its duly authorised agents
do  not,  prepare or submit any tax document (or any similar
document  relating to the tax affairs of the Vendor  or  any
company  under  its control) which comprises or  includes  a
claim,  election, surrender, disclaimer, notice or  consent,
or  withdraw  any  such item unless the  making,  giving  or
withdrawal of it (as the case may be) either has been  taken
into  account in preparing the Accounts, or could  not  have
any adverse effect on the liability to tax of the Company or
the  Subsidiary in respect of any accounting  period  ending
after Completion.

11.4  The Vendor or its duly authorised agent shall  deliver
all  tax documents which are required to be signed by or  on
behalf of the Company or the Subsidiary to the Purchaser for
authorisation,  signing and submission to the  relevant  tax
authority.  If a time limit applies in relation to  any  tax
document,   the  Vendor  shall  ensure  that  the  Purchaser
receives  the  tax document no later than 15  business  days
before the expiry of the time limit.

Obligations of the Purchaser

11.5 The Purchaser shall procure that:

(a)  the  Vendor and its duly authorised agents are afforded
     such  access  (including the taking of copies)  to  the
     books,  accounts  and records of the  Company  and  the
     Subsidiary  and such other assistance  as  it  or  they
     reasonably  require to enable the Vendor  to  discharge
     its  obligations under paragraph 11.2 and to enable the
     Vendor  and any member of the Retained Group to  comply
     with   its  own  tax  obligations  or  facilitate   the
     management or settlement of its own tax affairs;
     
(b)  the Vendor is promptly sent a copy of any communication
     from  any  tax authority insofar as it relates  to  the
     pre-Completion tax affairs;
     
(c)  there is given to such person or persons as may for the
     time  being  be  nominated by the Vendor  authority  to
     conduct  pre-Completion  tax  affairs,  and  that  such
     authority is confirmed to any relevant tax authority;
     
11.6  The Purchaser shall (subject to paragraph 11.7  below)
be  obliged  to procure that the Company and the  Subsidiary
shall   cause  any  tax  document  delivered  to  it   under
paragraph 11.4 to be authorised, signed and submitted to the
appropriate  tax authority without delay (and in  any  event
within any relevant time limit), and without amendment.

Rights of the Purchaser

11.7  The Purchaser shall be under no obligation to  procure
the authorisation, signing, or submission to a tax authority
of  any  tax  document delivered to it under paragraph  11.4
which  it  considers in its reasonable opinion to be  false,
misleading,   incomplete  or  inaccurate  in  any   material
respect,  but for the avoidance of doubt shall be  under  no
obligation  to  make any enquiry as to the  completeness  or
accuracy  thereof and shall be entitled to rely entirely  on
the Vendor and its agents.

11.8 The Vendor shall procure that:

(a)  the Purchaser is kept fully informed of the progress of
     all matters relating to the pre-Completion tax affairs;
     and
     
(b)  the  Purchaser promptly receives copies of all material
     written  correspondence with any tax authority  insofar
     as it is relevant to the pre-Completion tax affairs.
     
Conduct of other Tax Affairs

12.1  Subject  to  paragraph 8, the Purchaser  or  its  duly
authorised agents shall have sole conduct of all tax affairs
of   the   Company  and  the  Subsidiary   which   are   not
pre-Completion  tax affairs and shall be  entitled  to  deal
with  such  tax  affairs in any way  in  which  it,  in  its
absolute discretion, considers fit.

12.2  Notwithstanding the provisions of paragraph 12.1 above
the  Purchaser shall not, and shall procure that the Company
and the Subsidiary shall not, without the written consent of
the  Vendor,  take  any action under the provisions  of  any
enactment or regulation relating to tax if such action would
adversely  affect  the liability of the  Vendor  under  this
Schedule.

SIGNED by                     )
for and on behalf of          )    HEINZ ZULAUF
HOECHST AG  )
in the presence of:     Andrew Harris   )
                   65 Fleet Street
                   London EC4Y 1HS


SIGNED by                     )
for and on behalf of          )    INGRID WIIK
ALPHARMA (UK) LIMITED         )    CHARLES CROSTHWAITE
in the presence of:     Andrew Harris   )
                   65 Fleet Street
                   London EC4Y 1HS


SIGNED by                     )
for and on behalf of          )    EINAR SISSENER
ALPHARMA INC.                 )    ROBERT WROBEL
in the presence of:     Andrew Harris   )
                   65 Fleet Street
                   London EC4Y 1HS


                              
                              
                          ANNEXURES
                              
                           ANNEX A
                              
           Transfer Agreement for NorCox Pharma AB
                              
THIS AGREEMENT is made on          1998

Between

HOECHST  AKTIENGESELLSCHAFT a company  incorporated  in  and
under  the  laws of Germany with legal domicile  at  D-65926
Frankfurt am Main and registered at the commercial  Register
of  the  local  court Frankfurt am Main Abteilung  B,  under
registered number 14500 (the Vendor); and

  - with registered number - whose (registered) office is at
 ......... (the Purchaser).

Whereas

(A)   The  Vendor  and  the  Purchaser  are  to  execute  an
agreement (the Main Agreement) pursuant to which the  Vendor
agrees  to  sell  to the Purchaser the entire  issued  share
capital of Cox Investments Limited.  In addition to entering
into  the  Main Agreement, the parties hereto have  executed
this   Agreement,   together  with  three   other   transfer
agreements, in consideration of the Purchaser paying to  the
Vendor  GBP    (the Consideration), being that part  of  the
Purchase Price (as defined below) which is referable to  the
sale of the entire issued share capital of NorCox Pharma  AB
(the Company).

(B)   In  this Agreement, the Vendor agrees to sell and  the
Purchaser agrees to purchase the entire issued share capital
of  the Company (the Shares) for the Consideration and  upon
the  terms  set  out in this Agreement and,  to  the  extent
relevant, in the Main Agreement.

(C)   This  Agreement shall come into effect  simultaneously
with completion of the Main Agreement.

It is agreed as follows:

Definitions

In  this  Agreement, except so far as the context  otherwise
requires,  the  following  terms shall  have  the  following
meanings:

Limitations means, mutatis mutandis, the limitations on  the
Vendor's  liability  set  out  in  clause  7  of  the   Main
Agreement;

Purchase Price shall bear the meaning attributed thereto  in
clause 2.2 of the Main Agreement; and

Vendor's  Group  means  the Vendor, any  subsidiary  of  the
Vendor, any holding company of the Vendor and any subsidiary
of  such  holding company from time to time where subsidiary
and  holding  company shall be construed in accordance  with
sections 736 and 736A of the Companies Act 1985.


Condition precedent

1.    Completion of this Agreement shall be conditional upon
completion  of  the  Main Agreement in accordance  with  the
provisions of clause 3 thereof.


Sale of the shares and consideration

2.1  The Vendor agrees to sell (or procure the sale of), and
the  Purchaser hereby agrees to purchase, the Shares  as  at
and  with  effect from the date of this Agreement free  from
all  charges, liens, encumbrances, equities, claims or other
third party rights (including, without limitation, rights of
pre-emption)  of  any nature whatsoever, together  with  all
rights  which now are, or at any time hereafter may  become,
attached to them including, without limitation, the right to
receive all dividends and other distributions declared, made
or paid on or after the date of this Agreement.

2.2   The  Consideration shall be satisfied by the Purchaser
discharging its obligations pursuant to clause 3.3(a) of the
Main Agreement.

Completion

3.1   The sale and purchase of the Shares shall be completed
simultaneously  with  completion  of  the  Main   Agreement,
whereupon the events set out in the following provisions  of
this clause 3 shall take place.

3.2   The  Vendor shall deliver or cause to be delivered  to
the Purchaser:

(a)  share  certificates representing all  the  shares  duly
     endorsed  into  the  name  of  the  Purchaser  or   its
     nominees.
     
(b)  the Share Register of the Company
     
(c)  all  those documents evidencing the revocation  of  any
     existing mandates and powers of attorney given  by  the
     Company;
     
(d)  notice of resignation by the existing Board members.
     
Corporate Documents

4.    The  Registration  Certificate  and  the  Articles  of
Association, as set out in Appendix ... reflect the  present
status of the Company, and all documentation concerning  the
Company,  such  as  the  minutes  from  board  meetings  and
shareholders' meetings as well as books and accounts, are in
the  possession and safe custody of the Company and will  be
freely available to the Purchaser.

Warranties

5.    Subject to the Limitations, the Vendor warrants to the
Purchaser  as  at  the  date hereof  in  the  terms  of  the
warranties set out in the Schedule.


Waiver

6.     The   Purchaser  covenants  that  the  next  ordinary
shareholders' meeting of the Company will pass the necessary
resolutions,   whereby  the  present   directors   will   be
discharged   from   liability   with   respect   to    their
administration of the Company's affairs, provided,  however,
that  the Company's auditor will approve such discharge from
liability.

Entire agreement

7.    This  Agreement and, to the extent relevant, the  Main
Agreement  set  out  the entire agreement and  understanding
between  the parties in respect of the sale and purchase  of
the Shares.  It is agreed that:

(a)  no  party  has entered into this Agreement in  reliance
     upon any representation, warranty or undertaking of any
     other  party which is not expressly set out or referred
     to in this Agreement.
     
(b)  a  party  may claim in contract for breach of  warranty
     under this Agreement but, subject to clause 5(c), shall
     have no claim or remedy under this Agreement in respect
     of  misrepresentation (whether  negligent or otherwise,
     and  whether made prior to, and/or in, this  Agreement)
     or untrue statement made by any other party; and
     
(c)  This  clause  shall  not  exclude  any  liability   for
     fraudulent misrepresentation.
     
Counterparts

8.    This  Agreement may be entered into in any  number  of
counterparts   and  by  the  parties  to  it   on   separate
counterparts,  each of which, when executed  and  delivered,
shall  be  an  original,  but  all  the  counterparts  shall
together constitute one and the same instrument.


Invalidity

9.    If  any  provision of this Agreement  is  held  to  be
invalid or unenforceable, then such provision shall (so  far
as  it  is invalid or unenforceable) be given no effect  and
shall  be  deemed not to be included in this  Agreement  but
without invalidating any of the remaining provisions of this
Agreement.   The  parties  shall  then  use  all  reasonable
endeavours to replace the invalid or unenforceable provision
by  a  valid  provision the effect of which is as  close  as
possible   to  the  intended  effect  of  the   invalid   or
unenforceable provision.


Assignment

10.  Neither of the parties shall, without the prior written
consent  of the other, be entitled to assign the benefit  or
burden  of this Agreement in whole or in part save that  the
Vendor  may  assign its rights under this Agreement  to  any
member of the Vendor's Group.

Variation

11.   No variation of any of the terms of this Agreement (or
of  any  other documents referred to herein) shall be  valid
unless  it is in writing and signed by or on behalf of  each
of  the  parties  hereto.   The expression  variation  shall
include  any  variation, supplement, deletion or replacement
however effected.


Governing law

12.1  This  Agreement is governed by, and shall be construed
in accordance with the laws of England.

12.2 Each of the parties hereby irrevocably submits, for the
benefit  of the other, to the non-exclusive jurisdiction  of
the courts of England.

In  witness whereof this Agreement has been signed by and on
behalf  of  the  parties on the day and  year  first  before
written.




SIGNED by                     )
for and on the behalf of      )
HOECHST AG  )



SIGNED by                     )
for and on the behalf of                )
 ...................................               )

                          SCHEDULE
                              
                       The Warranties
                              
The Shares

1.    All of the Shares are fully-paid up, and the Vendor is
the  sole legal and beneficial owner of the Shares free from
all  security interests, options, equities, claims or  other
third party rights (including, without limitation, rights of
pre-emption) of any nature whatsoever.  The Vendor  has  the
legal right to dispose of the Shares.

Product Licences

2.    The  Appendix contains a list of all product  licences
held or beneficially owned by the Company or, in the case of
applications for product licences, of which the  Company  is
the applicant.



                              
                              
                           ANNEX B
                              
           Transfer Agreement for NorCox Pharma AS
                              
THIS AGREEMENT is made on          1998

Between

HOECHST  AKTIENGESELLSCHAFT a company  incorporated  in  and
under  the  laws of Germany with legal domicile  at  D-65926
Frankfurt am Main and registered at the commercial  Register
of  the  local  court Frankfurt am Main Abteilung  B,  under
registered number 14500 (the Vendor); and

  - with registered number - whose (registered) office is at
 ......... (the Purchaser).

Whereas

(A)   The  Vendor  and  the  Purchaser  are  to  execute  an
agreement (the Main Agreement) pursuant to which the  Vendor
agrees  to  sell  to the Purchaser the entire  issued  share
capital of Cox Investments Limited.  In addition to entering
into  the  Main Agreement, the parties hereto have  executed
this   Agreement,   together  with  three   other   transfer
agreements, in consideration of the Purchaser paying to  the
Vendor  GBP    (the Consideration), being that part  of  the
Purchase Price (as defined below) which is referable to  the
sale of the entire issued share capital of NorCox Pharma  AS
(the Company).

(B)   In  this Agreement, the Vendor agrees to sell and  the
Purchaser agrees to purchase the entire issued share capital
of  the Company (the Shares) for the Consideration and  upon
the  terms  set  out in this Agreement and,  to  the  extent
relevant, in the Main Agreement.

(C)   This  Agreement shall come into effect  simultaneously
with completion of the Main Agreement.

It is agreed as follows:

Definitions

In  this  Agreement, except so far as the context  otherwise
requires,  the  following  terms shall  have  the  following
meanings:

Limitations means, mutatis mutandis, the limitations on  the
Vendor's  liability  set  out  in  clause  7  of  the   Main
Agreement;

Purchase Price shall bear the meaning attributed thereto  in
clause 2.2 of the Main Agreement; and

Vendor's  Group  means  the Vendor, any  subsidiary  of  the
Vendor, any holding company of the Vendor and any subsidiary
of  such  holding company from time to time where subsidiary
and  holding  company shall be construed in accordance  with
sections 736 and 736A of the Companies Act 1985.


Condition precedent

1.    Completion of this Agreement shall be conditional upon
completion  of  the  Main Agreement in accordance  with  the
provisions of clause 3 thereof.


Sale of the shares and consideration

2.1  The Vendor agrees to sell (or procure the sale of), and
the  Purchaser hereby agrees to purchase, the Shares  as  at
and  with  effect from the date of this Agreement free  from
all  charges, liens, encumbrances, equities, claims or other
third party rights (including, without limitation, rights of
pre-emption)  of  any nature whatsoever, together  with  all
rights  which now are, or at any time hereafter may  become,
attached to them including, without limitation, the right to
receive all dividends and other distributions declared, made
or paid on or after the date of this Agreement.

2.2   The  Consideration shall be satisfied by the Purchaser
discharging its obligations pursuant to clause 3.3(a) of the
Main Agreement.

Completion

3.1   The sale and purchase of the Shares shall be completed
simultaneously  with  completion  of  the  Main   Agreement,
whereupon the events set out in the following provisions  of
this clause 3 shall take place.

3.2  (New) The Vendor shall deliver or cause to be delivered
to the Purchaser:

(a)  share  certificates representing all  the  shares  duly
     endorsed  into  the  name  of  the  Purchaser  or   its
     nominees.
     
(b)  the Certificate of Incorporation and the Share Register
     of   the  Company  with  an  updated  registration   of
     outstanding shares.
     
(c)  all  those documents evidencing the revocation  of  any
     existing mandates and powers of attorney given  by  the
     Company;
     
(d)  notice of resignation by the existing Board members.
     
Corporate Documents

4.    All  minute books (protocols) from the Board  meetings
and  Shareholders  Meetings as well as all  other  statutory
documents,  accounts,  auditors  reports,  as  well  as  all
agreements with shareholders (if any), are in the possession
and safe custody of the Company and will be freely available
to the Company.

Warranties

5.    Subject to the Limitations, the Vendor warrants to the
Purchaser  as  at  the  date hereof  in  the  terms  of  the
warranties set out in the Schedule.


Waiver

6.    The  Purchaser waives their right to advance liability
towards the members of the Board and the Purchaser covenants
that  the next ordinary shareholders' meeting of the Company
will  pass  the necessary resolutions, whereby  the  present
directors will be discharged from liability with respect  to
their administration of the Company's affairs.

Entire agreement

7.    This  Agreement and, to the extent relevant, the  Main
Agreement  set  out  the entire agreement and  understanding
between  the parties in respect of the sale and purchase  of
the Shares.  It is agreed that:

(a)  no  party  has entered into this Agreement in  reliance
     upon any representation, warranty or undertaking of any
     other  party which is not expressly set out or referred
     to in this Agreement.
     
(b)  a  party  may claim in contract for breach of  warranty
     under this Agreement but, subject to clause 5(c), shall
     have no claim or remedy under this Agreement in respect
     of  misrepresentation (whether  negligent or otherwise,
     and  whether made prior to, and/or in, this  Agreement)
     or untrue statement made by any other party; and
     
(c)  This  clause  shall  not  exclude  any  liability   for
     fraudulent misrepresentation.
     
Counterparts

8.    This  Agreement may be entered into in any  number  of
counterparts   and  by  the  parties  to  it   on   separate
counterparts,  each of which, when executed  and  delivered,
shall  be  an  original,  but  all  the  counterparts  shall
together constitute one and the same instrument.


Invalidity

9.    If  any  provision of this Agreement  is  held  to  be
invalid or unenforceable, then such provision shall (so  far
as  it  is invalid or unenforceable) be given no effect  and
shall  be  deemed not to be included in this  Agreement  but
without invalidating any of the remaining provisions of this
Agreement.   The  parties  shall  then  use  all  reasonable
endeavours to replace the invalid or unenforceable provision
by  a  valid  provision the effect of which is as  close  as
possible   to  the  intended  effect  of  the   invalid   or
unenforceable provision.


Assignment

10.  Neither of the parties shall, without the prior written
consent  of the other, be entitled to assign the benefit  or
burden  of this Agreement in whole or in part save that  the
Vendor  may  assign its rights under this Agreement  to  any
member of the Vendor's Group.

Variation

11.   No variation of any of the terms of this Agreement (or
of  any  other documents referred to herein) shall be  valid
unless  it is in writing and signed by or on behalf of  each
of  the  parties  hereto.   The expression  variation  shall
include  any  variation, supplement, deletion or replacement
however effected.


Governing law

12.1  This  Agreement is governed by, and shall be construed
in accordance with the laws of England.

12.2 Each of the parties hereby irrevocably submits, for the
benefit  of the other, to the non-exclusive jurisdiction  of
the courts of England.

In  witness whereof this Agreement has been signed by and on
behalf  of  the  parties on the day and  year  first  before
written.




SIGNED by                     )
for and on the behalf of      )
HOECHST AG  )



SIGNED by                     )
for and on the behalf of                )
 ...................................               )





                              
                              
                           ANNEX C
                              
       Transfer Agreement for Cox Pharma Belgium N.V.
                              
                           May 1998
                              
                              
                              
                              
                              
                         HOECHST AG
                              
                              
                              
                   ALPHARMA (U.K.) LIMITED
                              
                              
                              
                        ALPHARMA INC.
                              
                              
                              
                              
                              
                              
                              
                              
                              
                          AGREEMENT
  for the sale and purchase of the issued share capital of
                 Cox Pharma Belgium S.A./N.
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              


                              
                              
THIS AGREEMENT is made on  May 1998

Between

HOECHST  AKTIENGESELLSCHAFT a company  incorporated  in  and
under  the  laws of Germany with legal domicile  at  D-65926
Frankfurt am Main and registered at the commercial  Register
of  the  local  court Frankfurt am Main Abteilung  B,  under
registered number 14500 (the Vendor); and

ALPHARMA  (UK)  LIMITED (registered no. 3557686)  a  company
incorporated  in  and under the laws of  England  and  Wales
whose  registered  office is at Whiddon Valley,  Barnstaple,
Devon EX32 8NS, England (the Purchaser); and

ALPHARMA  INC. a company incorporated in and under the  laws
of  Delaware  whose principal place of business  is  at  One
Executive Drive, Fort Lee, New Jersey 07024, USA (Alpharma).

Whereas

(A)  Cox Pharma Belgium S.A./N.V. (the Company) is a limited
liability      company      ("societe     anonyme"/"naamloze
vennootschap")   incorporated   in   Belgium,   having   its
registered  office  at 155 rue Colonel  Bourg/Kolonel  Bourg
straat, 1140 Evere, Belgium, registered with the Register of
Commerce of Brussels under nr. 253.092, with an issued share
capital  of  BEF twelve million/12.000.000, fully  paid  up,
represented by Mr. J. Hus, Mr. O. Venema and Mr.  D.  Green,
with  registered  shares numbered 1 to  19.800  with/without
indication of nominale value (the Shares).

(B)   The  Vendor and Purchaser are to execute an  agreement
(the Main Agreement) pursuant to which the Vendor agrees  to
sell to the Purchaser the entire issued share capital of Cox
Investments Limited.  In addition to entering into the  Main
Agreement,  the parties hereto have executed this Agreement,
together   with   three   other  transfer   agreements,   in
consideration of the Purchaser paying to the Vendor  BP  (the
Consideration),  being that part of the Purchase  Price  (as
defined below) which is referable to the sale of the  entire
issued share capital of the Company.

(B)   In  this Agreement, the Vendor agrees to sell and  the
Purchaser agrees to purchase the entire issued share capital
of  the Company (the Shares) for the Consideration and  upon
the  terms  set  out in this Agreement and,  to  the  extent
relevant, in the Main Agreement.

(C)   This  Agreement shall come into effect  simultaneously
with completion of the Main Agreement.

It is agreed as follows:

Definitions

In  this  Agreement, except so far as the context  otherwise
requires,  the  following  terms shall  have  the  following
meanings:

Agreement  means the Agreement for the sale and purchase  of
the  issued  share capital of Cox Pharma Belgium  S.A./N.V.,
entered  into  between  the  Vendor  and  the  Purchaser  on
1998, substantially in the form of Annex C of the Annexes to
the Main Agreement;

BEF means Belgian Francs;

Company means Cox Pharma Belgium N.V./S.A., details of which
are set out in Schedule 1 hereto;

Main Agreement means the Agreement for the sale and purchase
of  the  issued  share  capital of Cox Investments  Limited,
entered  into  between  the Vendor an  d  the  Purchaser  on
April 1998;

Limitations means, mutatis mutandis, the limitations on  the
Vendor's  liability  set  out  in  clause  7  of  the   Main
Agreement;

Parties means the Purchaser and the Vendor;

Purchase Price shall bear the meaning attributed thereto  in
clause 2..2 of the Main Agreement;

Security Interest means any security interest of any  nature
whatsoever  including,  without  limitation,  any  mortgage,
hypotheek/hypotheque, charge, pledge,  lien,  assignment  by
way of security, voorrecht/privilege, beslag/saisie or other
incumbrance;

Shares  means  all the issued shares in the capital  of  the
Company; and

Warranties means the representations and warranties  out  in
Schedule 2 of the Main Agreement, it being understood  that,
for the terms of this Agreement, references to English legal
terms   for   any   action,  remedy,  methdo   of   judicial
proceedings,  legal document, legal status, court,  official
or  any other legal concept shall, in respect of Belgium, be
deemed  to  include  the  legal concept  which  most  nearly
approximates in Belgium to the English legal term.


Conditions precedent

1.1   Completion of this Agreement shall be conditional upon
the following conditions having been fulfilled :

(a)  completion of the Main Agreement in accordance with the
provisions of clause 3 thereof;

(b)   both  parties (i) being satisfied that the transaction
contemplated by this Agreement does not give rise to a  duty
to  notify under the provisions of the Law of 5 August  1991
on the protection of economic competition (the Law) or, (ii)
the  Vendor having received confirmation in writing from the
Belgian    Competition   Council   that   the    transaction
contemplated  by  this  Agreement is  either  admissible  or
deemed admissible pursuant to the provisions of the Law.

Quid  in  case notification is necessary ? Will  Parties  go
through with the transaction ?

1.2   Prior to the completion of this Agreement, the  Vendor
shall be the sole legal owner of all the Shares.


Sale of the shares and consideration

2.1  The Vendor agrees to sell (or procure the sale of), and
the  Purchaser hereby agrees to purchase, the Shares  as  at
and  with  effect from the date of this Agreement free  from
all    Security   Interests,   options,   charges,    liens,
encumbrances, equities, claims or other third  party  rights
(including,  without limitation, rights of  pre-emption)  of
any  nature whatsoever, together with all rights  which  now
are,  or at any time hereafter may become, attached to  them
including,  without  limitation, the right  to  receive  all
dividends and other distributions declared, made or paid  on
or after the date of this Agreement.

2.2   The  Consideration shall be satisfied by the Purchaser
discharging its obligations pursuant to clause 3.3(a) of the
Main Agreement.

Completion

3.1   The sale and purchase of the Shares shall be completed
simultaneously  with  completion  of  the  Main   Agreement,
whereupon the events set out in the following provisions  of
this clause 3 shall take place.

3.2   The  Vendor shall deliver or cause to be delivered  to
the Purchaser:

(a)  the   share   register  and  all   the   issued   share
     certificates,  if  any,  of the  Company,  to  be  duly
     amended  by  the  Parties so as to evidence  the  legal
     ownership of the Shares by the Purchaser;
     
(b)  the  By-laws  and all minute books and other  statutory
     books of the Company;
     
(c)  all  such  other  documents  (including  any  necessary
     waivers of pre-emption rights or other consents) as may
     be required to enable the Purchaser to be registered as
     the holder(s) of the Shares;
     
(e)  all  those documents evidencing the revocation  of  any
     existing mandates and powers of attorney given  by  the
     Company;
     
3.3  The Vendor and the Purchaser shall register or cause to
be  registered in the relevant Share Register of the Company
the transfer of the Shares pursuant to this Agreement.

Warranties

4.    Subject to the Limitations, the Vendor warrants to the
Purchaser  as  at  the  date hereof  in  the  terms  of  the
warranties set out in Schedule 2 of this Agreement.


Entire agreement

5.    This  Agreement and, to the extent relevant, the  Main
Agreement  set  out  the entire agreement and  understanding
between  the parties in respect of the sale and purchase  of
the Shares.  It is agreed that:

(a)  no  party  has entered into this Agreement in  reliance
     upon any representation, warranty or undertaking of any
     other  party which is not expressly set out or referred
     to in this Agreement.
     
(b)  a  party  may claim in contract for breach of  warranty
     under  this  Agreement but, subject  to  clause  5.(c),
     shall  have no claim or remedy under this Agreement  in
     respect  of  misrepresentation (whether   negligent  or
     otherwise, and whether made prior to, and/or  in,  this
     Agreement) or untrue statement made by any other party;
     and
     
(c)  this  clause  shall  not  exclude  any  liability   for
     fraudulent misrepresentation.
     
Counterparts

6.    This  Agreement may be entered into in any  number  of
counterparts   and  by  the  parties  to  it   on   separate
counterparts,  each of which, when executed  and  delivered,
shall  be  an  original,  but  all  the  counterparts  shall
together constitute one and the same instrument.


Invalidity

7.    If  any  provision of this Agreement  is  held  to  be
invalid or unenforceable, then such provision shall (so  far
as  it  is invalid or unenforceable) be given no effect  and
shall  be  deemed not to be included in this  Agreement  but
without invalidating any of the remaining provisions of this
Agreement.   The  parties  shall  then  use  all  reasonable
endeavours to replace the invalid or unenforceable provision
by  a  valid  provision the effect of which is as  close  as
possible   to  the  intended  effect  of  the   invalid   or
unenforceable provision.


Assignment

8.1  Neither of the parties shall, without the prior written
consent  of the other, be entitled to assign the benefit  or
burden  of this Agreement in whole or in part save that  the
Vendor  may  assign its rights under this Agreement  to  any
member of the Vendor's Group.

8.2  The Parties acknowledge and agree that if the Purchaser
assigns the benefit of this Agreement in whole or in part to
any  other person, the liabilities of the Vendor under  this
Agreement  to  the Purchaser shall be not greater,  and  not
less,  than  such  liabilities  would  have  been  had   the
assignment not occurred.

Variation

9.    No variation of any of the terms of this Agreement (or
of  any  other documents referred to herein) shall be  valid
unless  it is in writing and signed by or on behalf of  each
of  the  parties  hereto.   The expression  variation  shall
include  any  variation, supplement, deletion or replacement
however effected.


Governing law

10.1  This  Agreement is governed by, and shall be construed
in accordance with, the laws of Belgium.

10.2 Each of the parties hereby irrevocably submits, for the
benefit  of the other, to the non-exclusive jurisdiction  of
the courts of Brussels.

10.3 The agreement contained in clause 10.2 is included  for
the benefit of the Vendor.  Accordingly, notwithstanding the
exclusive agreement in clause 10.2, the Vendor shall  retain
the  right to bring proceedings in any other court which has
jurisdiction by virtue of the Convention on Jurisdiction and
the Enforcement of Judgments signed on 27 September 1968, as
amended and extended from time to time.

In  witness whereof this Agreement has been signed by and on
behalf  of  the  parties on the day and  year  first  before
written.




SIGNED by                     )


for and on the behalf of      )
HOECHST AG  )


SIGNED by                     )
for and on the behalf of                )





                              
                              
                         SCHEDULE 1
                              
                   Details of the Company
                              


1.   Name :              Cox Pharma Belgium S.A./N.V.

2.   Date of Incorporation :

3.   Place of Incorporation :

4.   Legal Form :        Societe Anonyme/Naamloze
Vennootschap

5.   Register of Commerce     Register of Commerce of
Brussels,
     and Register Number nr. 253.092

6.   Registered office :      155 rue Colonel Bourg/Kolonel
Bourg
                         straat, 1140 Evere, Belgium

7.   Directors :              Messrs. J. Hus, D. Green and
O. Venema

8.   Authorised Capital :

9.   Issued Capital :         BEF 12 million, fully paid up

10.  Shareholders :      - Hoechst AG, D-65926, Frankfurt am
Main,                           Germany
                         - Hoechst Marion Roussel Belgium
                           S.A./N.V., 155 rue Colonel Bourg,
1140
                           Evere, Belgium

11.  Accounting Reference
     Date

12.  Auditors :

13.  Tax Residence :

14.  Subsidiairies :          None

15.  Mortgages and Charges :

                              
                              
                         SCHEDULE 2
                              
                       The Warranties
                              
The Shares

1.    All of the Shares are fully-paid, or properly credited
as  fully-paid,  and  the  Vendor  is  the  sole  legal  and
beneficial  owner  of  the Shares  free  from  all  Security
Interests,  options, equities, claims or other  third  party
rights  (including,  without  limitation,  rights  of   pre-
emption) of any nature whatsoever.  The Vendor has the legal
right to dispose of the Shares.

Product Licences

2.    The  Appendix contains a list of all product  licences
held or beneficially owned by the Company or, in the case of
applications for product licences, of which the  Company  is
the applicant.

                              
                              
                              
                              
                          APPENDIX
                              
                           Part A
                              
         Product licences held or beneficially owned
                              
- -    Licence nr. 1277 from the Ministry of Public Health and
     Environment according to the Royal Decree dated 6  July
     1960,   as   amended  from  time  to  time,   for   the
     importation,   exportation   and   the    trading    of
     pharmaceutical specialities issued on February 7, 1997.
     


                              
                              
                           Part B
                              
              Applications for product licences
                              
                              
                              
                              
                              
                              
                              
                           ANNEX D
                              
          Transfer Agreement for NedCox Pharma B.V.
                              
                           May 1998
                              
                              
                              
                              
                              
                         HOECHST AG
                              
                              
                              
                              
                              
                   ALPHARMA (U.K.) LIMITED
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                        ALPHARMA INC.
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                          AGREEMENT
              for the sale and purchase of the
                   issued share capital of
                     Nedcox Pharma B.V.
                              


                              
                              
THIS AGREEMENT is made on  May 1998

Between

HOECHST  AKTIENGESELLSCHAFT a company  incorporated  in  and
under  the  laws of Germany with legal domicile  at  D-65926
Frankfurt am Main and registered at the commercial  Register
of  the  local  court Frankfurt am Main Abteilung  B,  under
registered number 14500 (the Vendor); and

ALPHARMA  (UK)  LIMITED (registered no. 3557686)  a  company
incorporated  in  and under the laws of  England  and  Wales
whose  registered  office is at Whiddon Valley,  Barnstaple,
Devon EX32 8NS, England (the Purchaser); and

ALPHARMA  INC. a company incorporated in and under the  laws
of  Delaware  whose principal place of business  is  at  One
Executive Drive, Fort Lee, New Jersey 07024, USA (Alpharma).

Whereas

(A)   The  Vendor and Purchaser are to execute an  agreement
(the Main Agreement) pursuant to which the Vendor agrees  to
sell to the Purchaser the entire issued share capital of Cox
Investments Limited.  In addition to entering into the  Main
Agreement,  the parties hereto have executed this Agreement,
together   with   three   other  transfer   agreements,   in
consideration of the Purchaser paying to the Vendor  BP  (the
Consideration),  being that part of the Purchase  Price  (as
defined below) which is referable to the sale of the  entire
issued  share  capital  of Nedcox  Pharma  B.V.,  a  private
company  with limited liability incorporated in and existing
under the laws of The Netherlands with its statutory seat in
Amsterdam,  and  its registered office at  Keienbergweg  41,
1101EX Amsterdam Zuidoast (the Company).

(B)   In  this Agreement, the Vendor agrees to sell and  the
Purchaser agrees to purchase the entire issued share capital
of  the Company (the Shares) for the Consideration and  upon
the  terms  set  out in this Agreement and,  to  the  extent
relevant, in the Main Agreement.

(C)   This  Agreement shall come into effect  simultaneously
with completion of the Main Agreement.

It is agreed as follows:

Definitions

In  this  Agreement, except so far as the context  otherwise
requires,  the  following  terms shall  have  the  following
meanings:

Limitations means, mutatis mutandis, the limitations on  the
Vendor's  liability  set  out  in  clause  7  of  the   Main
Agreement;

Purchase Price shall bear the meaning attributed thereto  in
clause 2..2 of the Main Agreement; and

Vendor's  Group  means  the Vendor, any  subsidiary  of  the
Vendor, any holding company of the Vendor and any subsidiary
of  such  holding company from time to time where subsidiary
and  holding  company shall be construed in accordance  with
sections 736 and 736A of the Companies Act 1985.


Condition precedent

1.    Completion of this Agreement shall be conditional upon
completion  of  the  Main Agreement in accordance  with  the
provisions of clause 3 thereof.


Sale of the shares and consideration

2.1  The Vendor agrees to sell (or procure the sale of), and
the  Purchaser hereby agrees to purchase, the Shares  as  at
and  with  effect from the date of this Agreement free  from
all  pledges  (pandrechter)  charges,  liens,  encumbrances,
equities,  claims  or other third party  rights  (including,
without  limitation, rights of pre-emption)  of  any  nature
whatsoever, together with all rights which now  are,  or  at
any  time  hereafter may become, attached to them including,
without  limitation, the right to receive all dividends  and
other  distributions declared, made or paid on or after  the
date of this Agreement.

2.2   The  Consideration shall be satisfied by the Purchaser
discharging its obligations pursuant to clause 3.3(a) of the
Main Agreement.

Completion

3.1   The sale and purchase of the Shares shall be completed
simultaneously  with  completion  of  the  Main   Agreement,
whereupon the events set out in the following provisions  of
this clause 3 shall take place.

3.2   The  Vendor shall deliver or cause to be delivered  to
the Purchaser:

(a)  a  certified copy of a duly executed notarial  deed  of
     transfer  of shares transferring into the name  of  the
     Purchaser  or  its nominee the Shares, to  be  executed
     before  civil-law notary H.BH. Kraak of  Stibbe  Simont
     Monahan Duhot in Amsterdam or his legal substitute;
     
(b)  a  copy  of  the  continuous text of  the  articles  of
     association of the Company as presently in force;
     
(c)  all  those documents evidencing the revocation  of  any
     existing mandates and powers of attorney given  by  the
     Company  [and evidencing the dismissal of  any  of  the
     managing directors [specify which] of the Company];
     
3.3  The  Vendor  and the Purchaser shall procure  that  the
     Company shall register in the Shareholdres' Register of
     the  Company  the transfer of Shares pursuant  to  this
     Agreement.
     
Warranties

4.    Subject to the Limitations, the Vendor warrants to the
Purchaser  as  at  the  date hereof  in  the  terms  of  the
warranties set out in the Schedule.


Entire agreement

5.    This  Agreement and, to the extent relevant, the  Main
Agreement  set  out  the entire agreement and  understanding
between  the parties in respect of the sale and purchase  of
the Shares.  It is agreed that:

(a)  no  party  has entered into this Agreement in  reliance
     upon any representation, warranty or undertaking of any
     other  party which is not expressly set out or referred
     to in this Agreement.
     
(b)  a  party  may claim in contract for breach of  warranty
     under  this  Agreement but, subject  to  clause  5.(c),
     shall  have no claim or remedy under this Agreement  in
     respect  of  misrepresentation (whether   negligent  or
     otherwise, and whether made prior to, and/or  in,  this
     Agreement) or untrue statement made by any other party;
     and
     
(c)  This  clause  shall  not  exclude  any  liability   for
     fraudulent misrepresentation.
     
Counterparts

6.    This  Agreement may be entered into in any  number  of
counterparts   and  by  the  parties  to  it   on   separate
counterparts,  each of which, when executed  and  delivered,
shall  be  an  original,  but  all  the  counterparts  shall
together constitute one and the same instrument.


Invalidity

7.    If  any  provision of this Agreement  is  held  to  be
invalid or unenforceable, then such provision shall (so  far
as  it  is invalid or unenforceable) be given no effect  and
shall  be  deemed not to be included in this  Agreement  but
without invalidating any of the remaining provisions of this
Agreement.   The  parties  shall  then  use  all  reasonable
endeavours to replace the invalid or unenforceable provision
by  a  valid  provision the effect of which is as  close  as
possible   to  the  intended  effect  of  the   invalid   or
unenforceable provision.


Assignment

8.   Neither of the parties shall, without the prior written
consent  of the other, be entitled to assign the benefit  or
burden  of this Agreement in whole or in part save that  the
Vendor  may  assign its rights under this Agreement  to  any
member of the Vendor's Group.

Variation

9.    No variation of any of the terms of this Agreement (or
of  any  other documents referred to herein) shall be  valid
unless  it is in writing and signed by or on behalf of  each
of  the  parties  hereto.   The expression  variation  shall
include  any  variation, supplement, deletion or replacement
however effected.


Governing law

10.1  This  Agreement is governed by, and shall be construed
in  accordance with, the laws of England.  The notarial deed
of transfer of shares, as referred to in clause 3.2(a) shall
be  governed  by, and shall be construed in accordance  with
the laws of The Netherlands.

10.2 Each of the parties hereby irrevocably submits, for the
benefit  of the other, to the non-exclusive jurisdiction  of
the courts of England.

In  witness whereof this Agreement has been signed by and on
behalf  of  the  parties on the day and  year  first  before
written.




SIGNED by                     )
for and on the behalf of      )
HOECHST AG  )


SIGNED by                     )
for and on the behalf of      )
                              )



                          SCHEDULE
                              
                       The Warranties
                              
The Shares

1.    All of the Shares are fully-paid up, and the Vendor is
the  sole legal and beneficial owner of the Shares free from
all  security interests, options, equities, claims or  other
third party rights (including, without limitation, rights of
pre-emption) of any nature whatsoever.  The Vendor  has  the
legal right to dispose of the Shares.

Product Licences

2.    The  Appendix contains a list of all product  licences
held or beneficially owned by the Company or, in the case of
applications for product licences, of which the  Company  is
the applicant.

                              
                              
                              
                              
                          APPENDIX
                              
                           Part A
                              
         Product licences held or beneficially owned
                              
                              
                              


                              
                              
                           Part B
                              
              Applications for product licences
                              
                              
                              
                              
                              
                              
                              
                              



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission